Assessing the risk of recurrence of colorectal adenomas using non-invasive methods
By detecting specific bacterial species in feces and calculating a comprehensive score, the problem of non-invasive assessment of colorectal adenoma recurrence has been solved, achieving highly accurate and low-invasive recurrence risk assessment and prevention.
Patent Information
- Application Number
- CN202180077828.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-06-03
- Filing Date
- 2021-11-18
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2041-11-18
AI Technical Summary
Current technology is not yet able to effectively assess whether colorectal adenomas recur after resection, especially in patients after polyp removal, where there is a lack of reliable non-invasive diagnostic methods.
By detecting baseline and follow-up levels of Clostridium nucleatum (Fn), Lachnoclostridium marker (m3), Clostridium hathaway (Ch), and Bacteroides clarus (Bc) in feces, a comprehensive score is calculated to determine whether an individual is at risk of recurrence of colorectal adenomas. PCR technology is used to determine the bacterial species level, and the risk of recurrence can be reduced through inhibitors.
This provides a non-invasive method to predict the risk of recurrence of colorectal adenomas, improving the accuracy and effectiveness of early detection, reducing the likelihood of recurrence, and decreasing the need for invasive examinations.
Smart Images

Figure CN116782950B_ABST
Abstract
Description
[0001] Related applications
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 116,104, filed November 19, 2020, and U.S. Provisional Patent Application No. 63 / 196,582, filed June 3, 2021, the contents of each of which are incorporated herein by reference in their entirety for all purposes. Background Technology
[0003] Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer death worldwide. Despite ongoing efforts to control new CRC incidence, both CRC incidence and mortality are rapidly increasing and trending upward in Asian countries. The continued global presence of CRC necessitates a paradigm shift in its management strategy, moving from clinical treatment to preclinical prevention. Early detection and appropriate treatment of colorectal adenomas (precancerous growths in the form of polyps or cysts) are crucial to preventing progression of colorectal cancer. Therefore, there is an urgent need for new and reliable methods to assess the likelihood of colorectal adenoma recurrence in patients, particularly those who have previously undergone polypectomy.
[0004] Microbial biomarkers have previously been shown to be useful for the non-invasive diagnosis of colorectal cancer and adenomas. However, it remains unclear whether such biomarkers can be used to predict adenoma recurrence in patients after resection of advanced adenomas. The inventors investigated microbial biomarkers in the stool of patients before and after colonoscopy following resection of colorectal adenomas, specifically Fusobacterium nucleatum (Fn), Bacteroides clarus (Bc), Clostridium hathewayi (Ch), Roseburia intestinalis (Ri), and the Lachnoclostridium biomarker m3. Significant increases in m3, Fn, and Ch, as well as a positive correlation between the combined score of the 4Bac (Fn, m3, Bc, and Ch) group, and recurrence was detected. Therefore, these fecal microbial biomarkers can be used for the non-invasive prediction of the risk of colorectal adenoma recurrence and for the diagnosis of adenoma recurrence. Therefore, this discovery provides a new, important, and improved means for the early detection of colorectal adenomas and the effective prevention of colorectal cancer, without the need for invasive procedures. Summary of the Invention
[0005] The inventors have discovered a correlation between recurrence of colorectal adenomas in patients who have previously undergone polyp removal surgery and elevated levels of certain bacterial species. Therefore, a first aspect of the invention provides a method for assessing the risk of a patient experiencing recurrent colorectal adenomas following a previous surgery to remove colorectal cancer or adenoma. The method comprises the following steps: (a) obtaining baseline levels of one or more of four bacterial species carrying the genetic marker m3, namely *Lachnoclostridium* (m3), *Fusobacterium nucleatum* (Fn), *Clostridium hathaway* (Ch), and *Bacteroides clarusensis* (Bc), from a first stool sample collected from the individual prior to resection of colorectal cancer or adenoma; (b) obtaining follow-up levels of one or more of Fn, m3, Bc, and Ch from a second stool sample collected from the individual after resection of colorectal cancer or adenoma; (c) calculating a composite score based on the baseline and follow-up levels of any one or more of the four bacterial species Fn, m3, Bc, and Ch using the method specified in Table 1; and (d) determining that the individual has an increased risk of colorectal adenoma recurrence if the value from step (c) is higher than a standard control value. Conversely, if the follow-up value is not higher than a standard control value, the individual is considered not to have an increased risk of colorectal adenoma recurrence. The standard control value is a composite score calculated based on baseline and follow-up levels of one (Fn or m3 or Ch), two (m3 and Fn, or m3 and Ch), three (Fn, m3 and Ch), or four bacterial species (Fn, m3, Bc, and Ch). This score was established from a control group of individuals who had not experienced recurrence of colorectal adenoma (e.g., approximately 3 to 10 years after resection of colorectal cancer or adenoma). In some cases, the claimed method for assessing the risk of recurrent colorectal adenoma in patients following a previous surgical resection of colorectal cancer or adenoma is performed according to the steps described above by determining the levels of one or more bacterial markers, said bacterial markers being determined based on the levels of one or more of the nucleotide sequences of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22.
[0006] Similarly, another method is provided for assessing an individual's risk of recurrence of colorectal adenoma after resection of colorectal cancer or adenoma. The method includes the following steps:
[0007] (a) The following values were obtained from stool samples collected from an individual after the removal of colorectal cancer or adenoma:
[0008] (1) The level of one or more of the three bacterial species carrying the gene marker m3: *Lachnoclostridium* species (m3), *Clostridium nucleatum* (Fn), and *Clostridium hathaway* (Ch); or
[0009] (2) A combined score of the levels of m3 and Ch in the two bacterial species, calculated as I2 + β5*m3 + β6*Ch; or
[0010] (3) The comprehensive score of the levels of the three bacterial species Fn, m3 and Ch was calculated as follows:
[0011] I3+β7*Fn+β8*m3+β9*Ch; or
[0012] (4) The comprehensive score of the levels of the four bacterial species Fn, m3, Bc, and Ch was calculated as follows:
[0013] I1+β1*Fn+β2*m3+β3*Bc+β4*Ch; and
[0014] (b) If a value from step (a) is detected to be higher than a standard control value, an individual is determined to have an increased risk of recurrent colorectal adenoma. The standard control value is a value of the same category (i.e., Fn level) or m3 or Ch; or a composite score calculated based on the levels of two (m3 and Ch), three (Fn, m3 and Ch), or four bacterial species (Fn, m3, Bc, and Ch), established from a control group of individuals who have not experienced recurrent colorectal adenoma (e.g., approximately 3 to 10 years after resection of colorectal cancer or adenoma). In some cases, the claimed method for assessing the risk of recurrent colorectal adenoma after a previous surgical resection of colorectal cancer or adenoma is performed by determining the levels of one or more bacterial markers, based on the nucleotide sequences of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22, according to the steps described above.
[0015] In some embodiments of either of the above methods, the individual has colorectal adenomas, such as polyps or cysts removed via polypectomy, or CRC surgically removed. In some embodiments, the combined score of any two, three, or four levels of the four bacterial species Fn, m3, Bc, and Ch is calculated using the method specified in Table 1. In some embodiments, the genome of m3 includes the nucleotide sequence of SEQ ID NO:19. In some embodiments, the genome of Ch includes the nucleotide sequence of SEQ ID NO:20. In some embodiments, the genome of Fn includes the nucleotide sequence of SEQ ID NO:21. In some embodiments, the genome of Bc includes the nucleotide sequence of SEQ ID NO:22. In some embodiments of either method, each of steps (a) and / or (b) includes obtaining the level of at least one of the bacterial species Fn, m3, Bc, and Ch, which is specific to DNA, RNA, or protein. In some embodiments of any method, each of steps (a) and / or (b) includes a polymerase chain reaction (PCR), such as quantitative polymerase chain reaction (qPCR) or reverse transcription-polymerase chain reaction (RT-PCR), for determining the level of bacterial species. In some embodiments of any method, a post-resection stool sample is collected from the individual approximately 1 to approximately 5 years after the initial resection of colorectal cancer or adenoma, for example, approximately one year after resection of colorectal cancer or adenoma. In some embodiments of any method, the method further includes, after determining in step (b) or (c) that the individual has an increased risk of colorectal adenoma recurrence, performing regular (e.g., annual) colonoscopies to monitor the individual or administering an inhibitor to the individual that inhibits or eliminates one or more of the bacterial species Fn, m3, Bc, and Ch, particularly in the individual and in the gastrointestinal tract. In some embodiments of any method, the inhibitor is a small repressive RNA or antisense oligonucleotide that specifically targets at least one or more genes of bacterial species Fn, m3, Bc, and Ch, or an expression cassette that directs the expression of the repressive RNA, or a viral vector comprising the expression cassette.
[0016] In a second aspect, the present invention provides a kit for assessing the risk of recurrence of colorectal adenoma in an individual after resection of colorectal cancer or adenoma, comprising: (1) a first container containing reagents for determining the level of bacterial species Fn; and (2) a second container containing reagents for determining the level of bacterial species m3. In some embodiments, the kit further comprises a third container containing one or more reagents for determining the level of bacterial species Bc. In some embodiments, the kit further comprises a third container containing one or more reagents for determining the level of bacterial species Ch.
[0017] In some embodiments, the reagents in each container are reagents for polymerase chain reaction (PCR), such as qPCR or RT-PCR. In some embodiments, the reagents in each container are reagents for detecting proteins specific to bacterial species such as Fn, m3, Bc, or Ch.
[0018] In a third aspect, the present invention provides a method for reducing the risk of recurrence of colorectal adenomas in an individual after resection of colorectal cancer or adenoma. The method comprises administering an effective amount of an inhibitor to the individual, said inhibitor inhibiting or eliminating one or more of the bacterial species Fn, m3, and Ch, particularly in the gastrointestinal tract of the individual.
[0019] In some embodiments, the inhibitor is a small repressive RNA or antisense oligonucleotide that specifically targets at least one gene of one or more bacterial species Fn, m3, and Ch, or an expression cassette that directs the expression of the repressive RNA, or a viral vector comprising the expression cassette. In some embodiments, the expression cassette is included within a viral particle. In some embodiments, the method further includes determining the levels of one or more bacterial species Fn, m3, and Ch in the feces of an individual after the administration step. In some embodiments, the administration step is performed within approximately one year after resection of colorectal cancer or adenoma. In some embodiments, the administration step is performed multiple times over a period of approximately one year to approximately five or ten years after the initial resection of colorectal cancer or adenoma (e.g., annually). In some embodiments, the target gene is within the nucleotide sequence of SEQ ID NO:19 (e.g., in the m3 genome), or within the nucleotide sequence of SEQ ID NO:20 (e.g., in the Ch genome), or within the nucleotide sequence of SEQ ID NO:21 (e.g., in the Fn genome).
[0020] In a fourth aspect, the present invention provides a kit for reducing the risk of recurrence of colorectal adenomas, comprising: (1) a first container containing one or more reagents for determining the levels of one or more bacterial species Fn, m3, and Ch; and (2) a second container containing a composition comprising an effective amount of an inhibitor that inhibits or eliminates one or more of bacterial species Fn, m3, and Ch. In some embodiments, the first container includes PCR reagents for determining the levels of DNA or RNA of one or more bacterial species Fn, m3, and Ch, such as primers or probes for PCR, for example, qPCR or RT-PCR. In some embodiments, the inhibitor is a small repressive RNA or antisense oligonucleotide that specifically targets at least one gene of one or more of bacterial species Fn, m3, and Ch, or an expression cassette that directs the expression of repressive RNA, or a viral vector comprising an expression cassette. Attached Figure Description
[0021] Figure 1 Changes in fecal bacterial markers in subjects after polypectomy compared to patients with baseline advanced adenomas. Figure 1 A) Subject recruitment strategies and sample / subject categories in this study. Figure 1 (B) Comparing the levels of four fecal bacterial markers between baseline stool samples collected before the diagnosis of advanced adenoma by index colonoscopy and follow-up stool samples collected before colonoscopy in subjects with paired baseline and follow-up stool samples in Group III who developed recurrent adenoma (R) and those who did not (no-R). Figure 1 (C) Comparison of the levels of four fecal bacterial markers between baseline and follow-up fecal samples from all subjects recruited in this study. Figure 1 In stool samples from patients with baseline adenomas (D1) and recurrent adenomas (D2), the levels of m3, Fn, and Ch did not differ between patients with proximal and distal lesions. Fn, Fusobacterium nucleatum; m3, Lachnoclostridium marker m3; Ch, Clostridium hathaway; Bc, Bacteroides clarus.
[0022] Figure 2 Baseline levels of four bacterial markers were between patients with and without recurrent adenomas. Figure 2 A) and follow-up (FU) Figure 2 Comparison of B) levels and their composite score 4Bac. Only patients with baseline and FU stool samples are included here to assess the effect of baseline and FU marker levels on predicting recurrent adenomas. no-R, no recurrence; R, recurrence; Fn, Fusobacterium nucleatum; m3, Lachnoclostridium m3 marker; Ch, Clostridium hathaway; Bc, Bacteroides clarusensis; 4Bac: composite score of Fn, m3, Ch, and Bc obtained by logistic regression.
[0023] Figure 3 The diagnostic performance of bacterial markers in predicting recurrent adenomas during follow-up (FU) surveillance. Figure 3 A) Receiver operating characteristic (ROC) curve analysis and diagnostic performance of Clostridium nucleatum (Fn), Lachnoclostridium m3, Clostridium hathaway (Ch), and the comprehensive score 4Bac were used to differentiate patients with and without recurrent adenomas. CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value. Figure 3 B) Performance of logistic regression models involving different biomarker groups in distinguishing between relapsed and non-relapsed patients. AUROC, region under ROC; no-R, no relapse; R, relapse.
[0024] Figure 4 Changes in bacterial markers at follow-up (FU) compared to baseline predict adenoma recurrence. Figure 4 A) Four bacterial markers and their composite score 4Bac showed no significant difference between baseline and FU stool in relapse-free patients. Significant increases in m3 and 4Bac were detected in FU stool compared to baseline stool in relapse-free patients. Figure 4 (B) Performance of logistic regression models involving changes in FU stool versus baseline stool in distinguishing between relapsed and non-relapsed patients. Models incorporating changes in Fn, m3, and Ch showed best performance. Fn, Fusobacterium nucleatum; m3, Lachnoclostridium marker m3; Ch, Clostridium hathaway; Bc, Bacteroides clarusensis; 4Bac: a combined score of Fn, m3, Ch, and Bc previously designed for the diagnosis of CRC and adenomas. no-R, no relapse; R, relapse.
[0025] Figure 5 Validate a novel logistic regression model involving the levels of Clostridium nucleatum (Fn), Lachnoclostridium marker m3, and Clostridium hathaway (Ch) in follow-up feces for the diagnosis of recurrent adenomas. Figure 5 The diagnostic performance of the new A model (A1) and FIT (A2) references colonoscopy and histological examination results. Figure 5 Comparison of the composite scores of patients with recurrent B-cell adenomas and those without recurrence, and ROC curve analysis of the composite scores. R, recurrence; no-R, no recurrence.
[0026] definition
[0027] In this disclosure, the terms "colorectal cancer (CRC)" and "colon cancer" have the same meaning and refer to cancer of the lower part of the large intestine (colon), the human digestive system, although rectal cancer usually refers more specifically to cancer of the last few inches of the colon or rectum. "Colorectal cancer cells" are colonic epithelial cells characteristic of colon cancer, and also encompass precancerous cells that are in the early stages of transforming into cancer cells or are prone to transforming into cancer cells. Such cells may exhibit one or more phenotypic characteristics of cancerous cells.
[0028] As used in this article, the term “colorectal adenoma” refers to a precancerous growth or precursor to CRC, which takes the form of a polyp or cyst and can progress to CRC if left untreated (usually by colonoscopy such as polypectomy or surgical removal).
[0029] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in single-stranded or double-stranded form and their polymers. Unless specifically defined, the term encompasses nucleic acids including known analogs of natural nucleotides that have similar binding properties to a reference nucleic acid and are metabolized in a manner similar to that of naturally occurring nucleotides. Unless otherwise stated, a specific nucleic acid sequence also implicitly encompasses its conserved variants (e.g., degenerate codon substitutions), alleles, orthologs, single nucleotide polymorphisms (SNPs), and complementary sequences, as well as explicitly stated sequences. Specifically, degenerate codon substitution can be achieved by producing a sequence in which the third position of one or more selected (or all) codons is replaced by a mixture of bases and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19: 5081 (1991); Ohtsuka et al., J. Biol. Chem. 260: 2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8: 91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.
[0030] The term "gene" refers to a segment of DNA involved in the production of a polypeptide chain; it includes the regions before and after the coding region (leader and tail) that are involved in the transcription / translation of the gene product and the regulation of transcription / translation, as well as the intercalation sequences (introns) between the individual coding segments (exons).
[0031] In this application, the terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein and refer to a polymer of amino acid residues. The term applies to amino acid polymers in which one or more amino acid residues are artificial chemical mimics of the corresponding naturally occurring amino acids, as well as to both naturally occurring and non-naturally occurring amino acid polymers. As used herein, the term covers amino acid chains of any length, including the target full-length protein, wherein the amino acid residues are linked by covalent peptide bonds.
[0032] The term "amino acid" refers to naturally occurring amino acids and synthetic amino acids, as well as amino acid analogs and amino acid mimics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic codon, as well as those subsequently modified, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. For the purposes of this application, amino acid analogs refer to compounds having the same basic chemical structure as naturally occurring amino acids, i.e., carbon atoms bound to hydrogen, carboxyl, amino, and R groups, such as homoserine, ortholeucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., ortholeucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. For the purposes of this application, amino acid mimics refer to compounds having a structure different from the usual chemical structure of amino acids, but functioning in a manner similar to naturally occurring amino acids.
[0033] Amino acids may include those that have non-naturally occurring D-chirality, as disclosed in WO01 / 12654, which can improve the stability (e.g., half-life), bioavailability, and other characteristics of peptides comprising one or more of these D-amino acids. In some cases, one or more, or possibly all, of the amino acids in a therapeutic peptide are D-chiral.
[0034] Amino acids can be represented in this article using either the commonly known three-letter symbols or the single-letter symbols recommended by the IUPAC-IUB Biochemistry Nomenclature Committee. Similarly, nucleotides can be represented using their generally accepted single-letter codes.
[0035] As used herein, the term "gene expression" refers to the transcription of DNA to form RNA molecules encoding a specific protein, or the translation of a protein encoded by a polynucleotide sequence. In other words, the term "gene expression level" in this disclosure encompasses both the mRNA level and the protein level encoded by the target gene.
[0036] An "expression cassette" is a recombinant or synthetically produced nucleic acid construct having a set of designated nucleic acid elements that allow transcription of a specific polynucleotide sequence in a host cell. This could be, for example, transcription of repressive RNA (e.g., miRNA or siRNA) or antisense RNA targeting a specific preselected sequence (e.g., a segment of *Clostridium nucleatum* (Fn), *Bacteroides clarus* (Bc), *Clostridium hathaway* (Ch), or a segment of the *Lachnoclostridium* species (m3) carrying the marker m3 genome sequence). An expression cassette can be part of a plasmid, a viral genome, or a nucleic acid fragment. In other words, an expression cassette can be transferred or delivered as part of a bacterial plasmid or a viral vector or virus-like particle. Typically, an expression cassette comprises a polynucleotide to be transcribed that is operatively linked to a promoter. In this context, "operatively linked" means placing two or more genetic elements (such as a polynucleotide coding sequence and a promoter) in relative positions that allow the elements to perform their appropriate biological functions (such as the promoter directing transcription of the coding sequence). Other elements that may be present in the expression cassette include elements that enhance transcription (e.g., enhancers) and terminate transcription (e.g., terminators), as well as elements that confer a binding affinity or antigenicity to the recombinant protein produced by the expression cassette.
[0037] As used in this application, “increase” or “decrease” refers to a detectable positive or negative change in quantity compared to a comparison control, such as an established standard control, critical value, or baseline value. An increase is typically a positive change of at least 10%, or at least 20%, or 50%, or 100% of the control value, and can be as high as at least 2 times, or at least 5 times, or even 10 times the control value. Similarly, a decrease is typically a negative change of at least 10%, or at least 20%, 30%, or 50%, or even as high as at least 80% or 90% of the control value. Other terms indicating a change or difference in quantity compared to a comparison benchmark, such as “more than,” “less than,” “higher than,” “lower than,” “greater than,” and “less than,” are used in this application in the same manner as described above. In contrast, the terms "essentially the same" or "essentially no change" indicate that there is a very small change or no change in quantity compared to the standard control value, typically within ±10%, or ±5%, ±2%, ±1%, or even smaller change compared to the standard control.
[0038] As used herein, the term "inhibiting / inhibition" refers to any detectable negative effect on a target biological process, such as RNA transcription, protein expression, cell proliferation, cell signal transduction, tumorigenesis, metastatic potential, and disease / condition recurrence. Typically, inhibition is reflected as a reduction of at least 10%, 20%, 30%, 40%, or 50% in the target process (e.g., the level of relevant bacteria such as Fn, Bc, Ch, or m3; or the incidence of colorectal adenomas) when the inhibitor is applied, compared to a control without inhibitor application.
[0039] As used herein, “primer” refers to an oligonucleotide that can be used in amplification methods such as polymerase chain reaction (PCR) to amplify a nucleotide sequence based on a polynucleotide sequence corresponding to a target gene (e.g., a specific polynucleotide sequence from the relevant bacterial species, such as gene markers m1704941 (from Fn), m370640 (from Bc), and m2736705 (from Ch), see, for example, WO2018 / 036503). For example, “primers” can be used in reverse transcription-polymerase chain reaction (RT-PCR) and quantitative polymerase chain reaction (qPCR) to quantify gene expression. Typically, at least one PCR primer used to amplify a polynucleotide sequence is sequence-specific to that polynucleotide sequence. The exact length of a primer depends on a variety of factors, including temperature, primer source, and the method used. For example, for diagnostic and prognostic applications, depending on the complexity of the target sequence, oligonucleotide primers typically contain at least 10, or 15, or 20, or 25 or more nucleotides, although they may contain fewer or more nucleotides. The factors involved in determining the appropriate primer length are well known to those skilled in the art. Primers used in specific embodiments are shown in the examples of this disclosure, illustrating their specific applications. In this disclosure, the term "primer pair" refers to a primer pair that hybridizes to the opposite strand of a target DNA molecule, or to a target DNA region located flanking the nucleotide sequence to be amplified. In this disclosure, the term "primer site" refers to a region of target DNA or other nucleic acid that hybridizes with the primer.
[0040] As used herein, the terms “amount” or “level” refer to the amount of a target bacterial species, such as Fn, Bc, Ch, or m3, present in a sample. Such amounts can be expressed as absolute values, i.e., the total amount of Fn, Bc, Ch, or m3 in the sample, or as relative values, i.e., the percentage of Fn, Bc, Ch, or m3 among all bacteria in the sample.
[0041] As used in this application, the term "treat / treating" describes actions that can eliminate, reduce, alleviate, reverse, or prevent or delay the occurrence or recurrence of any symptoms of the relevant condition. In other words, "treating" a condition encompasses both therapeutic and preventative interventions for that condition.
[0042] As used herein, the term "effective amount" refers to the amount of a given substance that is sufficient to produce the desired effect. For example, an effective amount of an inhibitor of a particular bacterial species such as Fn, Bc, Ch, or m3 is the amount of inhibitor that reduces (including to undetectable levels) the level of the bacterial species in the recipient's gastrointestinal tract (e.g., as measured in a fecal sample obtained from the recipient). As another example, an effective amount of an inhibitor is the amount that, when administered to a patient, achieves a detectable level that reduces the risk of recurrence of colorectal adenomas in the patient. An amount sufficient to achieve the desired effect in the context of treatment is defined as a "therapeutic effective dose." Dosage ranges vary depending on the nature of the therapeutic agent administered and other factors such as the route of administration and the severity of the patient's condition.
[0043] The term "antimicrobial agent" refers to any substance capable of inhibiting, suppressing, eliminating, or preventing the growth or proliferation of bacterial species such as Fn, Bc, Ch, or m3. Known agents with antimicrobial activity include various antibiotics that generally inhibit the proliferation of broad-spectrum bacterial species, as well as agents that can inhibit the proliferation of specific bacterial species, such as antisense oligonucleotides and small repressive RNAs.
[0044] "Percentage relative abundance," when used in context to describe a specific bacterial species (e.g., Fn, Bc, Ch, or m3) in relation to all bacterial species present in the same environment, refers to the relative abundance of the bacterial species within the total amount of all bacterial species, expressed as a percentage. For example, the percentage relative abundance of a particular bacterial species can be determined by comparing the amount of species-specific DNA or RNA in a given sample (e.g., determined by quantitative polymerase chain reaction (PCR) including reverse transcription (RT)-PCR) with the amount of all bacterial DNA in the same sample (e.g., determined by quantitative PCR including RT-PCR and sequencing based on 16S rRNA sequences).
[0045] When used in the context of describing the presence of a specific bacterial species (e.g., Fn, Bc, Ch, or m3) in a sample (e.g., a fecal sample collected from a test subject), “absolute abundance” refers to the amount of DNA from the bacterial species, out of the total amount of DNA in the sample. For example, the absolute abundance of a bacterium can be determined by comparing the amount of species-specific DNA for that bacterium in a given sample (e.g., determined by quantitative PCR including RT-PCR) with the total amount of DNA in the same sample.
[0046] As used herein, “total bacterial load” of a sample refers to the amount of all bacterial DNA out of the total amount of DNA in the sample. For example, the absolute abundance of bacteria can be determined by comparing the amount of bacterial-specific DNA (e.g., 16S rRNA determined by quantitative RT-PCR) in a given sample with the total amount of DNA in the same sample.
[0047] The terms "inhibitor," "activator," and "regulator" for relevant bacterial species (such as Fn, Bc, Ch, or m3) refer to inhibitory, activating, or regulatory molecules identified using in vitro and in vivo analyses, respectively, because they can actively or passively regulate bacterial proliferation or survival. The term "regulator" includes both inhibitors and activators. For example, an inhibitor is an agent that can partially or completely block, reduce, prevent, delay activation, inactivate, desensitize, or downregulate the level or amount of a related protein by inhibiting downstream effects, such as the growth or survival of colorectal cancer cells. In some cases, inhibitors bind directly or indirectly to target DNA or RNA, such as antisense molecules or microRNAs. As used herein, inhibitors are synonymous with inactivators and antagonists. For example, an activator is an agent that can stimulate, increase, promote, enhance activation, sensitize, or upregulate the level or amount of a related protein by promoting downstream effects, such as the growth or survival of colorectal cancer cells. Inhibitors, activators, and regulators can be macromolecules, such as polynucleotides, peptides including antibodies and antibody fragments, or they can be small molecules, including carbohydrate-containing molecules, siRNA, RNA aptamers, etc.
[0048] As used herein, a “standard control” refers to the average level of a preselected bacterial species found in a specific type of sample (e.g., a stool sample) obtained from an individual who has never had a recurrence of colorectal adenoma, or a composite score calculated based on the average levels of multiple bacterial species found in sample types collected from these individuals. For example, to examine patients who have undergone earlier surgery for colorectal cancer or adenoma resection, a “standard control” value is established to provide a cutoff value indicating whether the patient being examined has an elevated risk of colorectal adenoma recurrence. For a “standard control” to be properly established, a sufficient number of recurrence-free individuals (e.g., at least 10, 12, 15, 20, 24, or more individuals) must be included in the control group to provide samples to determine the average level of one or more preselected bacterial species, or a composite score calculated based on the levels of multiple bacterial species that represent the risk of colorectal adenoma recurrence.
[0049] As used herein, the term “about” refers to a range of values covering + / - 10% of a predetermined value. For example, “about 10” means 9 to 11.
[0050] In this disclosure, unless otherwise expressly stated otherwise, the term "or" is generally used in its meaning as including "and / or". Detailed Implementation
[0051] I. Introduction
[0052] Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. Patients undergoing polypectomy typically undergo follow-up colonoscopies to detect adenoma recurrence at recommended intervals. However, the association between gut microbiota composition and adenoma recurrence after polypectomy has not been investigated. A novel bacterial biomarker, m3, has previously been reported for non-invasive diagnosis of colorectal adenomas and cancer. In this disclosure, the inventors have identified novel fecal microbiome biomarkers to predict the risk of colorectal adenoma recurrence after polypectomy.
[0053] This study included 104 patients from the Polyp Surveillance Study between 2009 and 2019. Stool samples were collected prior to index colonoscopy (baseline) and surveillance colonoscopy (>6 months post-polyp removal). Recurrence was defined as the detection of new adenomas during colonoscopy after polyp removal. Four candidate biomarkers, including *Fusobacterium nucleatum* (Fn), *Lachnoclostridium* (m3), *Clostridium hathaway* (Ch), and *Bacteroides clarusensis*, were quantified in baseline and follow-up stool samples by quantitative polymerase chain reaction (qPCR). Fecal immunochemical testing (FIT) was performed on follow-up stool samples.
[0054] Each bacterial marker, Fn, m3, and Ch, detected in follow-up stool samples showed significant differences between subjects with recurrent adenomas and those without (n = 104; all P < 0.05). Logistic regression models incorporating Fn, m3, and Ch showed an area under the receiver operating characteristic curve (AUROC) of 0.741 (P < 0.0001) [sensitivity = 81.3%; specificity for predicting adenoma recurrence = 55.4%]. Adding FIT to the bacterial markers did not improve diagnostic accuracy. Among subjects paired between baseline and follow-up stool samples (n = 43), those who developed recurrent adenomas had higher levels of m3 (P = 0.006) and Fn (P = 0.07). Logistic regression models incorporating changes in stool Fn, m3, and Ch levels at follow-up compared to baseline showed an AUROC of 0.950 for predicting the risk of adenoma recurrence (P < 0.0001) [sensitivity = 90.0%; specificity = 87.0%]. Therefore, this study identified a new set of fecal microbiome biomarkers for predicting adenoma recurrence after polypectomy. These non-invasive biomarkers may improve colonoscopy monitoring programs.
[0055] II. General Method
[0056] The practice of this invention utilizes conventional techniques in the field of molecular biology. Basic textbooks disclosing the general methods used in this invention include: Sambrook and Russell, Molecular Cloning, A Laboratory Manual (3rd edition, 2001); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994).
[0057] For nucleic acids, sizes are given in kilobase pairs (kb) or base pairs (bp). Nucleic acid sizes are estimates derived from agarose or acrylamide gel electrophoresis, from sequenced nucleic acids, or from publicly available DNA sequences. For proteins, sizes are given in kilodaltons (kDa) or the number of amino acid residues. Protein sizes are estimates derived from gel electrophoresis, from sequenced proteins, from derived amino acid sequences, or from publicly available protein sequences.
[0058] For example, using the automated synthesizer described in Van Devanter et al., Nucleic Acids Res. 12:6159-6168 (1984), oligonucleotides not available commercially are synthesized chemically according to the solid-phase phosphoramidite method first described in Beaucage and Caruthers, Tetrahedron Lett. 22:1859-1862 (1981). The oligonucleotides are purified using any strategy recognized in the art, such as natural acrylamide gel electrophoresis or anion-exchange high-performance liquid chromatography (HPLC) as described in Pearson and Reanier, J. Chrom. 255:137-149 (1983).
[0059] The target sequence used in this invention can be verified using methods known in the relevant research field, such as the chain termination method for double-stranded templates in Wallace et al., Gene 16:21-26 (1981), for example, a polynucleotide sequence of DNA or RNA specific to the target bacterial species, as well as synthetic oligonucleotides (e.g., primers).
[0060] III. Sample Acquisition and Analysis of Bacterial DNA or RNA
[0061] This invention relates to determining the level or amount of identification marker DNA or RNA of one or more bacterial species found in human fecal samples, as a means of assessing the risk of recurrence of colorectal adenomas. Therefore, the first step in carrying out this invention is to obtain a fecal sample from a test subject and extract DNA or RNA from said sample.
[0062] A. Acquisition and preparation of fecal samples
[0063] Using the method of the present invention, stool samples are obtained from individuals to be tested for or monitored for recurrent colorectal adenomas. Individual stool sample collection can be readily performed in a clinic or at the patient's home. An appropriate amount of stool is collected and can be stored according to standard procedures prior to further preparation. Established techniques can be used to analyze bacterial DNA or RNA found in patient stool samples according to the present invention. Methods for preparing stool samples for nucleic acid extraction are well known to those skilled in the art. See, for example, Yu et al., Gut. September 25, 2015, pii:gutjnl-2015-309800.doi:10.1136 / gutjnl-2015-309800.
[0064] B. DNA and RNA extraction and quantification
[0065] Methods for extracting DNA from biological samples are well-known and routinely practiced in the field of molecular biology (e.g., described in Sambrook and Russell, Molecular Cloning: A Laboratory Manual, 3rd Edition, 2001). RNA contamination should be eliminated to avoid interfering with DNA analysis.
[0066] Similarly, there are many methods for extracting mRNA from biological samples. General methods for mRNA preparation can be followed, see, for example, Sambrook and Russell, ibid.; various commercially available reagents or kits, such as Trizol reagent (Invitrogen, Carlsbad, CA), Oligotex Direct mRNA kit (Qiagen, Valencia, CA), RNeasy Mini kit (Qiagen, Hilden, Germany), and... Series 9600 TM (Promega, Madison, WI) can also be used to obtain mRNA from biological samples of test subjects. Combinations of more than one of these methods can also be used. It is essential to remove all contaminating DNA from the RNA preparation. Therefore, samples should be carefully processed, thoroughly treated with DNase, and appropriate negative controls should be used in the amplification and quantification steps.
[0067] 1. PCR-based quantitative determination of DNA or RNA levels
[0068] When DNA or mRNA is extracted from a sample, the amount of bacterial DNA or RNA (such as 16S rDNA or RNA encoded by bacterial genes specific to the bacterial species) can be quantified. A preferred method for determining DNA or RNA levels is based on amplification methods, such as polymerase chain reaction (PCR), which includes reverse transcription-polymerase chain reaction (RT-PCR) for RNA quantification analysis.
[0069] When bacterial DNA is directly amplified, bacterial RNA must first be reverse transcribed. Prior to the amplification step, a DNA copy (cDNA) of the target RNA must be synthesized. This process is achieved through reverse transcription, which can be performed as a standalone step or in a homogeneous reverse transcription-polymerase chain reaction (RT-PCR), a modified polymerase chain reaction used for RNA amplification. Methods suitable for amplifying ribonucleic acid by PCR are described in: Romero and Rotbart, Diagnostic Molecular Biology: Principles and Applications pp. 401-406; Persing et al., Mayo Foundation, Rochester, MN, 1993; Egger et al., J. Clin. Microbiol. 33: 1442-1447, 1995; and U.S. Patent No. 5,075,212.
[0070] General methods of PCR are well known in the art and therefore are not described in detail herein. For a review of PCR methods, experimental protocols, and the principles of primer design, see, for example, Innis et al., PCR Protocols: A Guide to Methods and Applications, Academic Press, Inc., NY, 1990. PCR reagents and experimental protocols are also available from commercially available vendors such as Roche Molecular Systems.
[0071] In the most common scenario, thermostable enzymes are used to automate the PCR process. In this process, the temperature of the reaction mixture is automatically cyclicated through denaturation, primer annealing, and extension reaction zones. Instruments specifically designed for this purpose are commercially available.
[0072] Although PCR amplification of target bacterial DNA or RNA is typically used in the implementation of this invention, those skilled in the art will recognize that amplification of these DNA or RNA species in a sample can be achieved by any known method, such as ligase chain reaction (LCR), transcription-mediated amplification, and semi-conservative sequence replication or nucleic acid sequence-based amplification (NASBA), each of which provides adequate amplification. Recently developed branched-chain DNA technologies can also be used to quantitatively determine the amount of DNA or mRNA in a sample. For a review of branched-chain DNA signal amplification for the direct quantification of nucleic acid sequences in clinical samples, see Nolte, Adv. Clin. Chem. 33:201-235, 1998.
[0073] 2. Other quantitative methods
[0074] Other standard techniques well known to those skilled in the art can also be used to detect target bacterial DNA or RNA. While an amplification step is typically performed prior to the detection step, amplification is not always necessary in the methods of this invention. For example, DNA or RNA can be identified by size fractionation (e.g., gel electrophoresis) regardless of whether an amplification step is performed beforehand. After running the sample in an agarose or polyacrylamide gel and labeling it with ethidium bromide according to known techniques (see, for example, Sambrook and Russell, ibid.), the presence of a band of the same size as a standard control indicates the presence of target DNA or RNA, and the amount of said target DNA or RNA is then compared to the control based on the intensity of the band. Alternatively, oligonucleotide probes specific to target bacterial DNA or RNA can be used to detect the presence of such DNA or RNA, and the amount of bacterial DNA or RNA can be indicated by comparison with a standard control based on the intensity of the signal provided by the probe.
[0075] Sequence-specific probe hybridization is a well-known method for detecting specific nucleic acids, including those from other species. Under sufficiently stringent hybridization conditions, the probe hybridizes only with substantially complementary sequences. The stringency of the hybridization conditions can be relaxed to allow for varying amounts of sequence mismatches.
[0076] Many hybridization modalities are known in this field, including but not limited to liquid-phase, solid-phase, or mixed-phase hybridization analysis. The following articles provide a review of various hybridization analysis modalities: Singer et al., Biotechniques 4:230, 1986; Haase et al., Methods in Virology, pp.189-226, 1984; Wilkinson, In situ Hybridization, Wilkinson ed., IRL Press, Oxford University Press, Oxford; and Hames and Higgins eds., Nucleic Acid Hybridization: A Practical Approach, IRL Press, 1987.
[0077] The hybridization complex is detected using known techniques. Nucleic acid probes capable of specifically hybridizing with the target nucleic acid (i.e., bacterial 16S rDNA) can be labeled using any of several methods commonly used to detect the presence of hybridized nucleic acids. A commonly used detection method is to use... 3 H, 125 I, 35 S, 14 C or 32Autoradiography techniques using probes labeled with phosphorus (P, etc.). The choice of radioisotope depends on the parameters being studied, considering ease of synthesis, stability, and the half-life of the selected isotope. Other labels include compounds (e.g., biotin and digoxigenin) that bind to anti-ligands or antibodies labeled with fluorophores, chemiluminescent reagents, and enzymes. Alternatively, the probe can be directly conjugated to labels such as fluorophores, chemiluminescent reagents, and enzymes. The choice of label depends on the required sensitivity, ease of conjugation to the probe, stability requirements, and available instruments.
[0078] Using known techniques, the probes and primers required for carrying out this invention can be synthesized and labeled. For example, oligonucleotides used as probes and primers can be chemically synthesized using an automated synthesizer as described in Needham-Van Devanter et al., Nucleic Acids Res. 12:6159-6168, 1984, following the solid-phase phosphoramidite method first described in Beaucage and Caruthers, Tetrahedron Lett. 22:1859-1862, 1981. The oligonucleotides can be purified by natural acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson and Reanier, J. Chrom. 255:137-149, 1983.
[0079] IV. Quantification of bacterial proteins
[0080] A. Preparation of samples for bacterial protein detection
[0081] The presence of relevant bacterial species in a sample can also be quantitatively determined by analyzing one or more bacteria-specific proteins. Fecal samples from subjects are used to carry out this invention and can be obtained and processed for analysis according to known methods or as described in previous sections.
[0082] B. Determining bacterial protein levels
[0083] A variety of immunological analyses can be used to detect proteins, such as those indicating bacterial identity. In some implementations, a sandwich analysis can be performed by capturing the target protein from a test sample using antibodies with specific binding affinity for the protein. It can then be detected using labeled antibodies with specific binding affinity for said protein. Such immunological analyses can be performed using microfluidic devices, such as microarray protein chips. Target proteins (e.g., bacterial species-specific proteins) can also be detected by gel electrophoresis (such as two-dimensional gel electrophoresis) and Western blot analysis using specific antibodies. Alternatively, the target protein can be detected by standard immunohistochemical techniques using suitable antibodies. Monoclonal and polyclonal antibodies (including antibody fragments with desired binding specificity) can be used for the specific detection of target proteins. Antibodies and their binding fragments with specific binding affinity for particular proteins can be generated using known techniques.
[0084] In carrying out this invention, other methods can also be used to determine the levels of marker proteins. For example, a variety of techniques have been developed based on mass spectrometry to rapidly and accurately quantify target proteins (even in large samples). These methods involve high-precision instruments such as triple-Q instruments using multiple reaction monitoring (MRM) technology, matrix-assisted laser desorption / ionization time-of-flight tandem mass spectrometry (MALDI TOF / TOF), ion trap instruments using selective ion detection (SIM) mode, and QTOP mass spectrometers based on electrospray ionization (ESI). See, for example, Pan et al., J Proteome Res. 2009 Feb; 8(2):787–797.
[0085] V. Monitoring and treatment of recurrent colorectal adenomas
[0086] By illustrating the correlation between the enrichment of certain bacterial species in the human gut and an increased risk of recurrence of colorectal adenomas, this invention provides a preventative measure for the prophylactic treatment of patients at increased risk of recurrence of colorectal adenomas, despite prior resection of colorectal cancer or adenomas: The first measure is regular monitoring, such as scheduling annual colonoscopies for the patient, so that newly developed colonic polyps and cysts can be detected and removed immediately. The second measure is treating the patient with one or more inhibitors to suppress the relevant bacterial species and reduce their presence / level in the patient's gut.
[0087] Inhibitors of the relevant bacterial species can have virtually any chemical and structural properties: they can be peptides (e.g., antibodies, antibody fragments, aptamers), polynucleotides (e.g., antisense DNA / RNA, small repressive RNA, or microRNA), and small molecules. As long as they have a proven inhibitory effect on the target bacteria (e.g., inhibiting bacterial proliferation or inducing bacterial cell death), such inhibitors can be used to inhibit the development of recurrent adenomas in the patient's intestine, and therefore can be used to inhibit or prevent the recurrence of colorectal adenomas.
[0088] Furthermore, following previous surgical resection of colorectal cancer or polyp removal, the inventors demonstrated that the enrichment of certain bacterial species in the patient's gut is associated with an increased likelihood of colorectal adenoma recurrence, allowing the patient to be identified as having an increased risk of future adenoma development. As a result of this assay, the patient may require subsequent monitoring and treatment or preventative / monitoring measures to prevent, eliminate, improve, reduce severity and / or frequency, or delay the recurrence of colorectal adenomas. For example, physicians may prescribe pharmacological and non-pharmacological treatments, such as lifestyle modifications (e.g., losing 5% or more of body weight, adopting a healthier lifestyle including following a high-fiber / low-salt diet and maintaining a higher level of physical activity, such as walking at least 150 minutes per week, and undergoing more frequent regular screenings / examinations, such as colonoscopies every 1-2 years instead of every 5 years).
[0089] A. Regulators of related bacterial species
[0090] Bacterial species can be inhibited by using inhibitory nucleic acids that target specific bacterial genes (such as siRNA, microRNA, miniRNA, lncRNA, antisense oligonucleotides, and aptamers). These nucleic acids can be single-stranded nucleic acids such as mRNA or double-stranded nucleic acids such as DNA, which can be converted into the active form of the inhibitory RNA of the target bacteria under suitable conditions.
[0091] In one implementation, the nucleic acid encoding the inhibitor is provided in the form of an expression cassette, which is typically recombinantly generated and has a promoter operatively linked to a multinucleotide sequence encoding the inhibitor. In some cases, the promoter is a promoter that specifically directs expression in selected bacterial cells. Administration of such nucleic acids can suppress the expression of target bacterial genes and thus suppress bacterial populations. Since almost all known bacteria have been fully sequenced and the information is stored in databases, suitable inhibitor nucleic acids can be designed based on sequence information.
[0092] When bacterial cultures are exposed to candidate compounds, inhibitors of the relevant bacterial species can be identified in the analysis, and the effects of the compounds on the cultures can be analyzed. For example, inhibitors may be observed to exhibit an inhibitory or depressant effect on bacterial cultures, leading to reduced growth and / or increased bacterial cell death. An inhibitory effect is detected when a negative effect on bacterial cultures is established in the test group. Preferably, the negative effect is a reduction of at least 10%; more preferably, a reduction of at least 20%, 50%, 75%, 80%, or higher in cell proliferation.
[0093] As mentioned above, these bacterial inhibitors can have diverse chemical and structural characteristics. For example, an inhibitor can be any small or large molecule that affects only the growth or survival of a specific bacterial species. Essentially, any compound can be tested as a potential inhibitor. Such inhibitors can be identified by screening combinatorial libraries containing a large number of potentially effective compounds. As described herein, such combinatorial libraries can be screened in one or more analyses to identify those library members (specific chemical species or subclasses) exhibiting the desired characteristic activity. Therefore, the identified compounds can be used as conventional "lead compounds" or as potential or actual therapeutic agents on their own.
[0094] The preparation and screening of combinatorial chemical libraries are well known to those skilled in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, for example, U.S. Patent No. 5,010,175, Furka, Int. J. Pept. Prot. Res. 37: 487-493 (1991) and Houghton et al., Nature 354: 84-88 (1991)), and carbohydrate libraries (see, for example, Liang et al., Science, 274: 1520-1522 (1996) and U.S. Patent No. 5,593,853). Other chemical substances used to generate chemically diverse libraries may also be used.Such chemicals include, but are not limited to: peptide-like compounds (PCT Publication WO 91 / 19735), encoded peptides (PCT Publication WO 93 / 20242), random bio-oligomers (PCT Publication WO 92 / 00091), benzodiazepines (US Patent No. 5,288,514), diversomers such as hydantoin, benzodiazepines, and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90: 6909-6913 (1993)), and vinylogous peptides. polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114: 6568 (1992)), non-peptide peptide mimics with a β-D-glucose backbone (Hirschmann et al., J. Amer. Chem. Soc. 114: 9217-9218 (1992)), similar organic synthesis of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116: 2661 (1994)), oligourethanes (Cho et al., Science 261: 1303 (1993)) and / or peptide phosphonates (Campbell et al., J. Org. Chem. 59: 658 (1994)), nucleic acid libraries (see Ausubel, Berger and Sambrook, all ibid.), peptide nucleic acid libraries (see, e.g., US Patent No. 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature). BioteChnology, 14(3):309-314 (1996) and PCT / US96 / 10287), small organic molecule libraries (see, for example, benzodiazepines, Baum C&EN, January 18, p. 33 (1993)); isoprene, U.S. Patent No. 5,569,588; thiazolidinones and m-thiazinones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholine compounds, U.S. Patent No. 5,506,337; and benzodiazepines, U.S. Patent No. 5,288,514).
[0095] B. Pharmaceutical Composition
[0096] 1. Formulation
[0097] Inhibitors of relevant bacterial species can be used in the preparation of pharmaceutical compositions or drugs. These compositions or drugs can be administered to subjects to treat recurrent colorectal adenomas, particularly for prevention.
[0098] The compounds used in the treatment methods of the present invention can be used to prepare pharmaceutical compositions or drugs comprising an effective amount of the compounds, combined or mixed with excipients or carriers suitable for application.
[0099] Exemplary pharmaceutical compositions for such therapeutic uses include: (i) an expression cassette comprising a polynucleotide sequence encoding an inhibitor as described herein (e.g., siRNA, microRNA, tufa RNA, lncRNA, antisense oligonucleotide); and (ii) a pharmaceutically acceptable excipient or carrier. The terms “pharmaceutically acceptable” and “physiologically acceptable” are used synonymously herein. For use in therapeutic applications as described herein, an expression cassette may provide a therapeutically effective dose.
[0100] Inhibitors can be administered via liposomes, which serve to target conjugates to specific tissues and increase the half-life of the composition. Liposomes include emulsions, foaming agents, micelles, insoluble monolayers, liquid crystals, phospholipid dispersants, sheet-like layers, etc. In these formulations, the inhibitor to be delivered is included as part of the liposome, which is alone or in combination with molecules or other therapeutic or immunogenic compositions that can bind to receptors widely present in target cells, for example. Thus, liposomes filled with the inhibitors required by the present invention can be directed to a therapeutic site (e.g., the colon), whereby the liposomes deliver the selected inhibitor composition. The liposomes used in the present invention are formed from standard vesicle-forming lipids, which typically comprise neutral and negatively charged phospholipids and sterols (such as cholesterol). Factors such as liposome size, acid instability, and stability of the liposomes in the bloodstream are generally considered to guide lipid selection. Various methods for preparing liposomes are available, described, for example, in Szoka et al. (1980) Ann. Rev. Biophys. Bioeng. 9:467, U.S. Patent Nos. 4,235,871, 4,501,728 and 4,837,028.
[0101] Pharmaceutical compositions or drugs used in this invention can be prepared using standard techniques using one or more physiologically acceptable carriers or excipients. Suitable drug carriers are described herein and in EW Martin's "Remington's Pharmaceutical Sciences". The compounds and pharmaceutical agents of this invention, as well as their physiologically acceptable salts and solvates, can be formulated for administration via any suitable route, including inhalation, topical administration, nasal administration, oral administration, parenteral administration, or rectal administration.
[0102] Typical formulations for local or topical administration include creams, ointments, sprays, lotions, and plasters. However, pharmaceutical compositions can be formulated for any type of administration, local and systemic, such as intradermal, subcutaneous, intravenous, intramuscular, intranasal, intracerebral, intratracheal, intra-arterial, intraperitoneal, intravesical, intrapleural, intracoronary, or intratumoral administration using a syringe or other device. Formulations for administration by inhalation (e.g., aerosol), oral, rectal, or vaginal administration are also considered.
[0103] 2. Route of administration
[0104] Suitable formulations for topical application, such as to the skin and eyes, are preferably aqueous solutions, ointments, creams, or gels known in the art. Such formulations may contain solubilizers, stabilizers, tension enhancers, buffers, and preservatives.
[0105] Suitable formulations for transdermal administration include an effective amount of the modifier of the present invention accompanied by a carrier. Preferred carriers comprise absorbable, pharmaceutically acceptable solvents to facilitate penetration through the host skin. For example, a transdermal device may take the form of a bandage comprising a support member, a reservoir containing the compound and optionally a carrier, an optional rate-control barrier to deliver the compound to the host skin at a controlled and predetermined rate over a prolonged period, and means of securing the device to the skin. Matrix transdermal formulations may also be used.
[0106] For oral administration, the pharmaceutical composition or drug may be in the form of tablets or capsules prepared by conventional methods, for example, with pharmaceutically acceptable excipients. Preferred are tablets and gelatin capsules comprising: an active ingredient (i.e., an inhibitor or activator), and (a) a diluent or filler, such as lactose, glucose, sucrose, mannitol, sorbitol, cellulose (e.g., ethyl cellulose, microcrystalline cellulose), gum, pectin, polyacrylates and / or dicalcium phosphate, calcium sulfate, and (b) a lubricant, such as silica, talc, stearic acid, magnesium stearate or calcium stearate, metal stearates, colloidal silica, hydrogenated vegetable oil, corn starch, sodium benzoate, sodium acetate, and... / or polyethylene glycol; for tablets, it may also include (c) a binder, such as magnesium aluminum silicate, starch paste, gelatin, astragalus gum, methylcellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone and / or hydroxypropyl cellulose; and if desired, (d) a disintegrant, such as starch (e.g., potato starch or sodium starch), glycolate (ester), agar, alginate or its sodium salt, or a foaming mixture, (e) a wetting agent, such as sodium lauryl sulfate, and / or (f) absorbents, colorants, flavorings and sweeteners.
[0107] Tablets can also be film-coated or sausage-coated using methods known in the art. Liquid formulations for oral administration can be in the form of, for example, solutions, syrups, or suspensions, or they can be provided as dry products for reconstitution with water or other suitable media prior to use. Such liquid formulations can be prepared by conventional methods using pharmaceutically acceptable additives, such as, suspending agents (e.g., sorbitol syrup, cellulose derivatives, or hydrogenated edible fats); emulsifiers (e.g., lecithin or gum arabic); non-aqueous media (e.g., almond oil, esters, ethanol, or graded vegetable oils); and preservatives (e.g., methylparaben, propylparaben, or sorbic acid). Depending on the application, the formulation may also contain buffer salts, flavoring agents, coloring agents, and / or sweeteners. Where necessary, oral formulations can be appropriately formulated to achieve controlled release of the active compound.
[0108] The compounds and pharmaceutical preparations of the present invention can be formulated for parenteral administration by injection, for example by rapid bolus injection or continuous infusion. Injectable formulations can be provided in unit dose form, for example, ampoules or multi-dose containers with added preservatives. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and more preferably suppositories prepared from fat emulsions or suspensions. The compositions can be sterile and / or contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers, solubilizers, osmotic pressure-regulating salts and / or buffers. Alternatively, the active ingredient can be in powder form, reconstituted with a suitable medium (e.g., sterile, pyrogen-free water) before use. Furthermore, they may contain other substances of therapeutic value. The compositions are prepared according to conventional mixing, granulation, or coating methods, and contain about 0.1% to 75%, preferably about 1% to 50%, of the active ingredient.
[0109] For administration by inhalation, a suitable propellant can be used to conveniently deliver the active ingredient as an aerosol from a pressurized pack or nebulizer. The propellant, for example, is dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gases. In the case of pressurized aerosols, a valve can be provided to determine the dosage unit for delivery of a measured amount. For example, gelatin capsules or gelatin cartridges used in inhalers or blowpipes can be prepared as a powder mixture containing the compound and a suitable powder matrix (e.g., lactose or starch).
[0110] The regulator can also be formulated into rectal compositions, such as suppositories or retention enemas, for example, containing conventional suppository bases, such as cocoa butter or other glycerides.
[0111] Furthermore, the active ingredient can be formulated into a reservoir formulation. Such a long-acting formulation can be administered via implantation (e.g., subcutaneous or intramuscular) or intramuscular injection. Thus, for example, the active ingredient can be formulated with a suitable polymeric or hydrophobic material (e.g., as an emulsion in an acceptable oil) or ion exchange resin, or it can be formulated into a poorly soluble derivative, such as a poorly soluble salt.
[0112] In some cases, the pharmaceutical compositions or medicaments of the present invention comprise: (i) an effective amount of a compound as described herein that inhibits a population of one or more related bacterial species identified herein, and (ii) another therapeutic agent. When used with the compounds of the present invention, such therapeutic agents may be used alone, sequentially, or in combination with one or more other such therapeutic agents (e.g., a first therapeutic agent, a second therapeutic agent, and the antimicrobial inhibitor of the present invention). Administration may be carried out via the same or different routes of administration or may be carried out within the same pharmaceutical formulation.
[0113] 3. Dosage
[0114] The drug composition or drug may be administered to the subject at a therapeutically effective dose that can prevent, treat, or control recurrence of colorectal adenomas as described herein. The drug composition or drug may be administered to the subject in an amount sufficient to elicit a valid therapeutic response in the subject.
[0115] The dosage of the active agent administered depends on the individual's weight, age, individual condition, surface area or volume of the area to be treated, and the form of administration. The dosage is also determined by the presence, nature, and extent of any adverse reactions associated with the administration of the specific compound to a particular subject. For example, each type of inhibitor or the nucleic acid encoding the inhibitor may have a unique dosage. A unit dose for oral administration to a mammal weighing approximately 50 to 70 kg may contain approximately 5 to 500 mg of the active ingredient. Generally, the dosage of the active compound of the present invention is sufficient to achieve the desired effect. The optimal dosing regimen can be calculated from measurements of drug accumulation in the subject. Typically, the dosage can be administered once or more daily, weekly, or monthly. Those skilled in the art can readily determine the optimal dosage, method of administration, and repetition rate.
[0116] To achieve the desired therapeutic effect, compounds or agents can be administered multiple times over a therapeutically effective daily dose. Therefore, to treat the relevant disease state or disease described herein in a subject, a therapeutically effective administered compound requires periodic (e.g., daily) dosing for three days to two weeks or longer. Typically, the agent is administered for at least three consecutive days, usually at least five consecutive days, more usually at least ten consecutive days, and sometimes for 20, 30, 40, or more consecutive days. While continuous daily dosing is the preferred route to achieve a therapeutically effective dose, a beneficial therapeutic effect can be achieved even without daily administration, provided that the dosing is repeated frequently enough to maintain a therapeutically effective concentration of the agent in the subject. For example, the agent can be administered every other day, every three days, or, if a higher dose range is used and tolerated by the subject, once weekly.
[0117] The optimal dosage, toxicity, or therapeutic efficacy of the compound or agent may vary depending on the relative potency of the individual compound or agent and can be determined by standard pharmaceutical methods in cell cultures or laboratory animals, for example, by determining the LD50. 50 (The dose that causes 50% of the population to die) and ED 50 (The dose that is effective in 50% of the population). The dose ratio of toxic effects to therapeutic effects is the therapeutic index and can be expressed as the ratio LD50. 50 / ED 50 Drugs exhibiting a high therapeutic index are preferred. Although drugs exhibiting toxic side effects can be used, consideration should be given to designing delivery systems that can target such drugs to affected tissue sites, thereby minimizing potential damage to normal cells and reducing side effects.
[0118] For example, data obtained from cell culture analysis and animal studies can be used to determine dosage ranges for human use. The preferred dosage ranges for such compounds are those including ED. 50 However, this applies within a range of circulating concentrations with low or no toxicity. The dosage can vary within this range, depending on the dosage form and route of administration. For any agent used in the method of this invention, the therapeutically effective dose can first be estimated from cell culture analysis. Dosages can be established in animal models to achieve the IC50 values determined in cell culture. 50 The range of circulating plasma concentrations (the concentration at which half of the maximum symptom suppression is achieved). This information can be used to determine the dosage available to humans more precisely. For example, plasma levels can be determined by high-performance liquid chromatography (HPLC). Typically, for a typical subject, the dose equivalent of the drug is approximately 1 ng / kg to 100 mg / kg.
[0119] Exemplary doses of the inhibitors or nucleic acids encoding the inhibitors described herein are provided. When administered intravenously, the dose of the nucleic acid encoding the inhibitor (such as an expression vector) may be 0.1–0.5 mg (e.g., 5–30 mg / kg). Small organic compound inhibitors may be administered orally in doses of 5–1000 mg orally, or intravenously infused at a rate of 10–500 mg / ml. Peptide inhibitors may be administered intravenously or by infusion at the following rates: 50–500 mg / ml (over 120 minutes); 1–500 mg / kg (over 60 minutes); or 1–100 mg / kg (rapid bolus), five times weekly. Inhibitors may be administered subcutaneously in doses of 10–500 mg; intravenously in doses of 0.1–500 mg / kg twice daily; or approximately 50 mg once weekly; or 25 mg twice weekly.
[0120] The pharmaceutical compositions of the present invention can be administered alone or in combination with at least one other therapeutic compound. Exemplary advantageous therapeutic compounds include systemic and local anti-inflammatory drugs, analgesics, antihistamines, anesthetic compounds, etc. Other therapeutic compounds can be administered co-administered with the main active ingredient, or even in the same composition. Other therapeutic compounds can also be administered alone in a single composition or in a dosage form different from that of the main active ingredient. A portion of the main ingredient can be administered co-administered with other therapeutic compounds, while other doses can be administered alone, depending on the specific findings of the intestinal bacterial community and the characteristics of the individual.
[0121] The dosage of the pharmaceutical composition of the present invention can be adjusted during treatment based on various factors, including the distribution of the patient's gut microbiota and physiological response to the treatment regimen. Those skilled in the art typically participate in adjusting such treatment regimens.
[0122] VI. Reagent Kits and Devices
[0123] The present invention provides compositions and kits for carrying out the methods described herein to assess the risk of recurrence of colorectal adenomas by determining the level or relative abundance of one or more of relevant bacterial species such as Fn, Bc, Ch and m3 in a sample, such as a fecal sample, obtained from a human patient who has previously had colorectal cancer, cysts, or polyps removed by surgery or polypectomy. For example, measuring the level or relative abundance of one or more of Fn, Bc, Ch, and m3 in a stool sample collected from a patient allows the patient to be treated accordingly. For instance, if a patient is considered likely to have recurrent colorectal adenoma, the patient will receive more monitoring, such as being scheduled for colonoscopies more frequently (e.g., annually instead of every 5 years), being prescribed changes to diet and physical activity protocols, up to and including antimicrobial therapy to suppress the levels of relevant bacterial species, such as Fn, Bc, Ch, and m3 (e.g., administration of expression cassettes, such as those contained in viral vectors, that direct the expression of repressive RNA molecules, particularly in colorectal epithelial tissue, to suppress the expression of one or more genes of Fn, Bc, Ch, or m3); otherwise, the patient will not receive more monitoring but will maintain a regular monitoring schedule, such as a colonoscopy every 5 years for individuals at average risk. In any case, when a patient undergoes screening for potentially recurrent colorectal adenomas (e.g., via colonoscopy), any abnormal colorectal tissue (cysts, polyps, and tumors, including adenomas and carcinomas, etc.) discovered in this way can be removed according to established procedures.
[0124] In assessing the likelihood of recurrent colorectal adenomas in multiple patients who have undergone colorectal cancer / polyp / cyst resection, patients who have undergone CRC / polyp / cyst resection and whose postoperative stool samples show a significant percentage increase in the levels or relative abundance of Fn, Bc, Ch, or m3, or their combined score, compared to the corresponding baseline levels or scores in their preoperative stool samples, are considered to have a higher chance of developing recurrent colorectal adenomas than patients who have undergone CRC / polyp / cyst resection and whose postoperative percentage increase from baseline values is smaller or nonexistent. Therefore, patients who undergo CRC / polyp / cyst resection receive more monitoring (e.g., more frequent colonoscopies, such as annually instead of every 5 years) and treatment (e.g., antimicrobial therapy, especially antimicrobial therapy targeting one or more bacterial species Fn, Bc, Ch, or m3) compared to patients who may receive less monitoring and / or treatment, including regularly scheduled colonoscopies and / or no antimicrobial therapy at all, especially if patients who are considered to have no increased risk of colorectal adenoma recurrence.
[0125] In patients identified as having an increased risk of recurrence of colorectal adenomas and therefore given antimicrobial therapy to prevent or reduce the risk of recurrence, their stool samples may be further tested after antimicrobial therapy to determine the levels of bacterial species Fn, Bc, Ch, or m3, or a combination thereof, to confirm the risk reduction.
[0126] In some embodiments, kits for analyzing the levels or relative abundance of at least one optional plurality of bacterial species Fn, Bc, Ch, or m3 typically include reagents for performing RT-PCR or qPCT to qualitatively and / or quantitatively determine polynucleotide sequences, such as species-specific 16S rRNA: for example, at least one oligonucleotide for reverse transcription and at least a set of three oligonucleotide primers for PCR amplification of the specific polynucleotide sequence. In some cases, one or more oligonucleotides may be labeled with a detectable moiety. In some cases, the kit includes a hydrolysis probe to allow for immediate quantification of the amplification product. Typically, the hydrolysis probe has a fluorescent label and a quencher. Examples of such primers and probes are provided in the Examples section of this disclosure.
[0127] Typically, the kit also includes positive and negative controls for specific analytical methods. Furthermore, the kit of this invention can provide instruction manuals to guide users in analyzing samples and assessing the likelihood of recurrent colorectal adenomas in test subjects.
[0128] On the other hand, the invention can also be implemented in an apparatus or system comprising one or more such apparatuses capable of performing all or part of the method steps described herein. For example, in some cases, after receiving a first sample (e.g., a stool sample from a test subject prior to surgery such as polypectomy to remove colorectal cancer / polyps / cysts) and a second sample of the same type (e.g., a stool sample from the same test subject post-surgery, e.g., about one, two, or about one to two, three, four, or five years post-surgery), the apparatus or system performs the following steps to assess the likelihood of recurrence of colorectal adenoma in the subject: (a) determining the level or relative abundance (e.g., based on their characteristic 16S) of one or more bacterial species Fn, Bc, Ch, or m3 in the first and second samples. (a) a composite score of the level or relative abundance of any two, three, or four of these species (e.g., Fn and m3, optionally further including Ch) calculated according to the description provided herein, optionally further including a FIT score; (b) comparing the level or composite score of the first sample with the level or composite score of the second sample; (c) providing an output indicating whether the test subject has a high risk of recurrent colorectal adenoma and therefore should be subject to preventive monitoring and / or treatment as described herein to eliminate or reduce such risk. In some cases, the device or system of the present invention performs the tasks of steps (b) and (c) after step (a) has been performed and the level or composite score from step (a) has been input into the device.
[0129] Preferably, the apparatus or system of the present invention is partially or fully automated.
[0130] Example
[0131] The following examples are provided for illustrative purposes only and not for limitation. Those skilled in the art will readily recognize that various non-critical parameters can be changed or modified to produce substantially the same or similar results.
[0132] Example I
[0133] introduction
[0134] Colorectal cancer (CRC) is one of the most common cancers worldwide[1]. Most CRCs begin as adenomas and gradually develop into cancer. Colonoscopic polypectomy has been used as a first-line method for the prevention of CRC. In patients undergoing colonoscopy screening, 20% to 40% of adenomatous polyps can be detected, and their occurrence is associated with an increased risk of CRC. Although endoscopic resection of colorectal adenomas significantly reduces the risk of CRC, regular monitoring is still necessary because the risk of recurrence after polypectomy is 37% to 60%[2]. Recently, new biomarkers for the diagnosis of CRC have been developed, including fecal DNA[3], plasma DNA[4], and fecal bacterial markers[5]. The U.S. Food and Drug Administration (FDA) has approved two non-invasive tests, one for multi-target fecal DNA[3] and the other for plasma DNA testing for CRC screening[4]. However, these tests have low accuracy in diagnosing precancerous lesions, especially non-advanced adenomas, because genetic or epigenetic changes in cancer cells are rarely seen in small precancerous lesions.
[0135] Altered gut microbiota composition is associated with the occurrence and progression of adenomas and CRC [6-10]. In particular, the direct pathogenic role of the gut microbiota in CRC development has been demonstrated in germ-free animal models
[11] . Specific bacterial pathogens, such as Fusobacterium nucleatum (Fn) [12-14] and anaerobic Peptostreptococcus
[15] , have been identified as promoting colorectal tumors. Fecal bacterial biomarkers have previously been reported as non-invasive detection methods for adenomas and CRC [5,7,16,17]. Quantification of candidate bacterial biomarkers using probe-based double-stranded quantitative polymerase chain reaction (qPCR) analysis has shown that a group of fecal bacterial biomarkers, including Fn, Lachnoclostridium m3, Clostridium / Hungatella hathewayi (Ch), and Bacteroides clausti (Bc) (the so-called 4Bac group of Fn, m3, Ch, and Bc), has shown good diagnostic performance for adenomas and CRC [5,16]. These bacterial markers have been hypothesized to be effective in detecting recurrent adenomas. In this study, the inventors evaluated the utility of the 4Bac group (Fn, m3, Ch, and Bc) in predicting the risk of adenoma recurrence after colonoscopic polypectomy.
[0136] Materials and methods
[0137] Study subjects
[0138] This study included a portion of a polyp surveillance study conducted at Prince of Wales Hospital, a secondary and tertiary referral centre of the Chinese University of Hong Kong (CREC reference number: 2010.198), between 2009 and 2019. All participants provided stool samples prior to an index colonoscopy (baseline). Participants found to have adenomas during the index colonoscopy underwent polypectomy and were scheduled for regular colonoscopies according to international polyp surveillance guidelines [2,18,19]. No recurrence during surveillance colonoscopies was defined as no adenoma, sessile serrated polyp, no hyperplastic polyp larger than 10 mm, or no CRC detected on colonoscopy. Recurrence was defined as the presence of at least one adenoma on colonoscopy. To identify new lesions, only polypectomies occurring at least 6 months after the index colonoscopy were included. The adenoma detection rate on colonoscopy was >30%. Stool samples were collected prior to each surveillance colonoscopy. The study included three groups of participants: Group I: 118 patients with adenomas, whose stool samples were collected prior to the index colonoscopy (baseline samples); Group II: 61 participants, whose stool samples were collected during the colonoscopy (follow-up samples); and Group III: 43 participants, whose baseline and follow-up samples were matched prior to the colonoscopy. Figure 1 (A) All lesions were confirmed by an experienced pathologist (TKF). Advanced adenoma was defined as an adenoma 1 cm or larger with tubular or villous components, or with high or severe dysplasia. Exclusion criteria included subjects who had taken antibiotics within the past 3 months. Informed consent was obtained from all subjects. This study was approved by the NTEC-CUHK Joint Clinical Research Ethics Committee.
[0139] Human fecal sample collection
[0140] Baseline stool samples were collected prior to index colonoscopy in Group I (n=118) and Group III (n=43) (n=161). Of these, 104 follow-up stool samples were collected 2.5 ± 1.6 years after index colonoscopy and prior to monitoring colonoscopy, from Group II (n=61) and Group III (n=43). Of the 104 patients who underwent polypectomy, 48 (28 in Group II and 20 in Group III) were found to have adenomas during follow-up colonoscopy. Figure 1 Of the 7 patients (A), 7 had advanced adenomas. Detailed clinical characteristics are shown in Table 4. Stool samples were collected from subjects in standardized containers at home and immediately stored in their home freezer at -20°C. Frozen samples were then delivered to the hospital in insulated polystyrene foam containers and immediately stored at -80°C until further analysis.
[0141] Fecal DNA was extracted and quantified using dual quantitative PCR (qPCR) and probe-based bacterial markers.
[0142] Fecal DNA was extracted using the Norgen Fecal DNA Isolation Kit (Norgen Biotek Corp, Ontario, Canada) following the manufacturer's instructions. DNA quality and quantity were determined using gel electrophoresis and a NanoDrop spectrophotometer. Fecal levels of four bacterial DNA markers (Fn, m3, Bc, and Ch) were quantified by qPCR, covering markers previously shown to be enriched in CRC (Fn and Ch), adenoma, and CRC (m3) patient samples, as well as healthy subject (bc) samples. The targeting specificity of the primer and probe sequences for the markers and 16S rDNA internal controls has been validated in our previous studies [5,16]. Each probe was accompanied by a 5' reporter dye FAM (6-carboxyfluorescein) or VIC (4,7,2'-trichloro-7'-phenyl-6-carboxyfluorescein) and a 3' quenching dye TAMRA (6-carboxytetramethyl-rhodamine). Primers and hydrolysis probes were synthesized by Invitrogen (Carlsbad, CA). As previously described, qPCR amplification was performed on the ABI QuantStudio sequencing system with thermal cycling parameters of 95°C for 10 minutes and (95°C for 15 seconds, 60°C for 1 minute) × 45 cycles [5,16]. Each experiment included a positive control and a negative control for the biomarker (H2O as a template). Each sample was tested in triplicate. Compared with the internal control (Power(2,-(Cq... 靶 -Cq 对照 In contrast, the relative level of each marker is calculated using the delta Cq method and displayed as a Log value of '*10e6+1'.
[0143] Scoring algorithms and thresholds
[0144] The composite score of the four bacterial markers (4Bac) using a logistic regression model (4Bac score = I1 + β1*Fn + β2*m3 + β3*Bc + β4*Ch) was determined in a previous study [5]. The composite scores of the follow-up markers using the logistic regression model are as follows: I2 + β5*m3 + β6*Ch, or I3 + β7*Fn + β8*m3 + β9*Ch (Table 2). The composite scores of the baseline and follow-up markers using the logistic regression model are as follows: I 10 +(β i *Fn 随访 –β j *Fn 基线 )+(β k *m3 随访 –β l *m3 基线 )+(β m *Ch随访 –β n *Ch 基线 (Table 1). In the regression model, I represents the intercept, β represents the regression coefficient, and the marker represents the corresponding Cq value. The critical value was determined by receiver operating characteristic (ROC) analysis, which maximized the Youden index (J = sensitivity + specificity - 1)
[20] .
[0145] Fecal immunochemical test (FIT)
[0146] Quantitative OC sensor tests were performed on an automated OC sensor instrument (Eiken Chemical, Japan) following the manufacturer’s instructions, using a positive threshold equivalent to 100 ng hemoglobin concentration per milliliter (ng Hb / mL).
[0147] Statistical analysis
[0148] Numerical values are expressed as median (interquartile range) or mean ± SD (as applicable). Differences in bacterial levels were determined by the Mann-Whitney U test or paired t-test. Continuous clinical and pathological variables were compared by t-test or one-way ANOVA. ROC curves were used to assess the diagnostic value of bacterial markers or models in differentiating patients with or without recurrent adenomas. Pairwise comparisons of the area under the ROC (AUROC) for each method / marker were performed using nonparametric methods
[21] . All tests were performed using Graphpad Prism 5.0 (Graphpad Software Inc., San Diego, CA) or MedCalc Statistical Software V.18.5 (MedCalc Software bvba, Ostend, Belgium; website: medcalc.org; 2018). P < 0.05 was considered statistically significant.
[0149] result
[0150] Increased fecal bacterial markers in subjects with recurrent adenomas
[0151] The levels of four bacterial markers, Fn, Ch, m3, and Bc, were first compared in baseline stool samples from patients with advanced adenomas and in follow-up stool samples from subjects with or without recurrent adenomas after polypectomy. Compared to baseline stool samples, Fn (P<0.05) and m3 (P<0.0001) were significantly increased in follow-up stool samples from subjects with recurrent adenomas, but these markers did not change significantly in follow-up samples from subjects without recurrence in Group III (Mann-Whitney test). In follow-up samples from subjects without recurrence, the marker Ch was decreased (P=0.066), but this did not change significantly in follow-up samples from patients with recurrent adenomas in Group III compared to baseline stool samples. The marker Bc did not show any change in follow-up stool samples compared to the corresponding baseline samples, regardless of adenoma recurrence status. Figure 1 (B). These findings were further validated in an expanded dataset involving all samples from groups I through III. Compared to baseline stool, Fn and m3 were significantly increased in follow-up stool of subjects with recurrent adenomas, while Ch was significantly decreased in follow-up stool of subjects without recurrent adenomas (both P < 0.05). Figure 1 (C). Regardless of the adenoma recurrence status, the biomarkers Bc remained unchanged in follow-up stool compared to baseline. Importantly, stool levels of Fn, m3, and Ch did not show differences between patients with proximal and distal lesions in subjects with recurrent adenomas. Figure 1 D1 and Figure 1 (D2). These findings suggest that after endoscopic resection of advanced adenomas, CRC or adenoma-rich bacterial markers are increased in the stool of subjects with adenoma recurrence or decreased in the stool of subjects without adenoma recurrence.
[0152] The levels of fecal bacterial markers differed between subjects with recurrent and non-recurrent adenomas.
[0153] To assess whether fecal bacterial markers during indexing and monitoring colonoscopies were correlated with colonoscopy outcomes, subjects were divided into two groups based on baseline and follow-up fecal samples: “recurrent” (n=20; 46.5%) and “no recurrence” (n=23; 53.5%). No significant differences were found in the levels of bacterial markers detected at follow-up between subjects with adenoma recurrence and those without, based on baseline fecal sample levels. Figure 2 (A). At the follow-up time point, the levels of Fn (P<0.01), m3 (P<0.001), and Ch (P<0.05), as well as the previously designed 4Bac comprehensive score (Fn, m3, Ch, and Bc) for CRC / adenoma diagnosis (P<0.001), were observed to be significantly higher in subjects with recurrent adenoma than in subjects without recurrence. Figure 2(B). These results suggest that quantifying bacterial markers during surveillance and follow-up can help predict patients at high risk of adenoma recurrence.
[0154] Adding FIT did not improve the prediction of adenoma recurrence.
[0155] Further, all follow-up stool samples were included to evaluate the performance of bacterial markers at follow-up time points in predicting adenoma recurrence. ROC curve analysis showed that individual Fn, m3, and Ch markers significantly distinguished between subjects with recurrent adenoma and those without recurrence, with AUROC values of 0.640, 0.676, and 0.597, respectively (all P < 0.05), while FIT failed to distinguish between subjects with recurrent adenoma and those without recurrence (AUROC = 0.551, P = 0.38). Figure 3 The A3 m3 assay outperformed Fn and Ch in predicting adenoma recurrence, with a sensitivity of 52.0% and a specificity of 80.4%. Although Ch showed a relatively small AUROC, it had a specificity of 100% and a sensitivity of 20.8% in predicting adenoma recurrence. In contrast, FIT showed limited sensitivity (8.3%) in detecting recurrent adenomas, most of which were non-late-stage adenomas.
[0156] With a specificity of 71.4%, the combined score using 4Bac performed well in distinguishing between patients with recurrent and non-recurrent adenomas, with an AUROC of 0.701 (P = 0.0001) and a sensitivity of 62.5%. However, since 4Bac was not significantly superior to other individual biomarkers (P > 0.05 by comparing ROC curves), combining different biomarker groups or different scoring algorithms to ensure better predictive accuracy was necessary. Therefore, logistic regression was applied to combine bacterial biomarkers. The logistic regression model involving m3 and Ch showed an AUROC of 0.725 (P < 0.0001), a sensitivity of 62.5%, and a specificity of 80.4%. The model combining Fn, m3, and Ch showed the highest AUROC of 0.732 (P < 0.0001) for predicting adenoma recurrence, with a sensitivity of 81.3% and a specificity of 55.4%. Figure 3 (B). Inclusion of FIT results was not associated with improved diagnostic performance of bacterial markers.
[0157] The fecal bacterial markers (m3, Fn, and Ch) group showed high accuracy in predicting adenoma recurrence.
[0158] Changes in fecal bacterial marker levels during colonoscopy were further compared with fecal samples collected prior to index colonoscopy. Compared with baseline samples from subjects with confirmed adenoma recurrence via colonoscopy, significantly increased m3 levels and a composite score of 4Bac were found in follow-up fecal samples (P < 0.05 by paired test). Figure 4 (A). In contrast, in follow-up samples from subjects who subsequently underwent routine colonoscopy during the monitoring period, the levels of bacterial markers did not change significantly (P>0.05). Using a logistic regression model that included changes in fecal bacterial markers at follow-up compared to baseline stool, m3 alone showed good diagnostic performance in predicting adenoma recurrence, with an AUROC of 0.843 (P<0.0001), a sensitivity of 85.0%, and a specificity of 87.0%. Although the numbers were not statistically significant ( Figure 4 The results were better than those using the 4Bac score. Combining Fn or Ch (instead of Bc) with m3 in the model further improved the diagnostic performance of m3 alone, although this was not significant. The combination of m3, Fn, and Ch performed best in predicting adenoma recurrence, with an AUROC of 0.950 (P < 0.0001), a sensitivity of 90.0%, and a specificity of 87.0%. Figure 4 (B).
[0159] A combination of fecal bacterial markers for predicting adenoma recurrence
[0160] Tables 1 and 2 list the AUROC, sensitivity, and specificity results for various combinations of fecal bacterial biomarkers from different groups, along with the corresponding calculation methods if more than one biomarker is used. The risk of adenoma recurrence can be predicted, depending on the fecal bacterial biomarker group used, by (1) comparing individual levels or composite scores in samples collected from baseline and follow-up, or (2) using standard controls (Table 1 or Table 2) in samples collected at follow-up, at the individual level or composite score.
[0161] Table 1. Examples of fecal bacterial marker combinations for predicting adenoma recurrence and their corresponding calculation methods (baseline and follow-up comparison).
[0162]
[0163] Table 2 Examples of fecal bacterial marker combinations for predicting adenoma recurrence and their corresponding calculation methods (compared to standard controls)
[0164]
[0165] discuss
[0166] This is the first study to demonstrate that fecal bacterial biomarkers can effectively predict the risk of adenoma recurrence after polypectomy. By quantifying changes in the levels of novel bacterial biomarkers during colonoscopy compared to levels at index colonoscopy, the inventors found that these biomarkers have high accuracy in predicting adenoma recurrence, with a sensitivity of 90%. These findings highlight the role of noninvasive fecal biomarkers in improving adenoma surveillance programs.
[0167] Microbial biomarkers have previously been identified for the diagnosis of colorectal adenomas via metagenomic sequencing [7], and qPCR tests have been developed for potential clinical applications [5,16]. The qPCR test involves four bacterial biomarkers, including Fn and Ch, which are found to be enriched in the feces of patients with CRC, m3, which is enriched in the feces of patients with adenomas and CRC, and Bc, which is enriched in the feces of normal subjects. The levels of m3 and the composite 4Bac score have shown considerable accuracy in detecting late-stage and non-late-stage lesions, suggesting that these bacterial biomarkers are sensitive for detecting small adenomas [5]. Several studies have shown that microbial dysbiosis is associated with the etiology of colorectal adenomas
[22] . For example, changes in the composition of the gut microbiota in fecal samples and adenomatous tissue have been reported [8,23]. Unlike existing non-invasive CRC screening tests, such as multi-target fecal DNA or plasma DNA tests, which target genetic / epigenetic changes in cancer cells and are rarely found in non-late-stage adenomas, the bacterial markers disclosed herein can be used to detect adenomas and are particularly useful in detecting early or small precancerous lesions, which account for more than 30% of adenomas detected during colonoscopy.
[0168] It has been reported that the gut microbiota underwent moderate alterations 3 months after adenoma resection, but major phyla, including Fusobacterium, did not change significantly
[24] . Although the gut microbiota composition of patients with adenomas is not expected to change substantially after lesion resection, the gut microbiota can be readily remodeled by lifestyle, diet, and nutrient intake. Altered gut microbiota can promote or inhibit the development of colorectal cancer, and changes in the microbiota associated with adenomas may represent early events leading to CRC pathways. The results of this study showed that the bacterial markers Fn and m3 for CRC or enriched adenomas were persistently increased in the feces of subjects with recurrent adenomas, while Ch decreased in the feces of subjects without recurrence. Importantly, there were no differences in the levels of fecal m3, Fn, and Ch in subjects with recurrent proximal colonic adenomas compared with subjects with recurrent distal colonic adenomas, indicating that the sensitivity of these markers is not affected by lesion location. These findings support the potential clinical application of bacterial markers Fn, m3, and Ch in the detection of recurrent adenomas. Furthermore, it is possible to modulate the gut microbiota to a healthier state to reduce the risk of developing colorectal cancer, although this should be evaluated in prospective studies.
[0169] The inventors developed two strategies for predicting adenoma recurrence, including either individual follow-up stool samples or paired baseline and follow-up stool samples. Their data showed that m3 outperformed Fn and Ch in predicting adenoma recurrence in both strategies, while combining Fn and Ch improved the diagnostic performance of m3 in both strategies. The combination of m3, Fn, and Ch produced the best AUROC compared to other models. However, the addition of Bc and FIT did not increase the diagnostic sensitivity for recurrent adenoma. Fn has been shown to induce inflammation and modulate the host immune response to promote tumor development [12,13]. Ch has been shown to promote colonic epithelial cell proliferation in mouse models
[25] . These bacterial species are believed to trigger a host immune response to further promote the development of recurrent adenoma. Therefore, inhibiting these bacteria could effectively help reduce the risk of adenoma recurrence.
[0170] There is an urgent need for non-invasive biomarkers to monitor adenoma recurrence. Current guidelines recommend colonoscopy at different time intervals after polyp removal based on the characteristics of the lesions (including size, number, histology, and location) [2,19], but colonoscopy is invasive and has low rates of regularity due to poor adherence. A recent national survey showed that patients prefer stool-based tests to colonoscopy when undergoing CRC screening
[26] , highlighting the importance of considering patient preferences in colorectal screening recommendations.
[0171] This study has several advantages. It is the first prospective study to collect stool samples regularly for up to 10 years from patients after polypectomy. Each individual sampled in this study underwent a full colonoscopy, providing complete visualization of the colon from rectum to cecum; colonoscopy is considered the most reliable reference standard for determining the presence or absence of polyps. Polyps removed during colonoscopy were reviewed and classified by experienced gastrointestinal pathologists. Finally, this study includes predictive algorithms based on bacterial markers known to be enriched / depleted in both adenoma and non-adenoma groups.
[0172] In summary, this study demonstrates that fecal bacterial biomarkers, including Fn, m3, and Ch, can be used to diagnose recurrent adenomas after polypectomy. Therefore, this study provides the first fecal microbiome-based strategy for colorectal tumor surveillance.
[0173] Example II
[0174] method
[0175] Subject recruitment and stool sample collection in a prospective validation cohort
[0176] A further prospective study was conducted, recruiting subjects who had adenoma resection within the past five years and were scheduled for regular colonoscopies at the Prince of Wales Hospital of the Chinese University of Hong Kong between May and October 2021. Consecutive eligible subjects provided follow-up stool samples one week prior to bowel preparation for colonoscopy. Subjects whose stool samples were collected were excluded if they had taken antibiotics within three months prior to stool collection. Colonoscopies and histological examinations were performed on the cohort. Subjects collected stool samples in standard containers with preservatives (Norgen, Canada), which showed minimal changes in the microbial community observed at room temperature after 7 days compared to fresh frozen samples in previous studies [5]. Samples were delivered to the hospital within 24 hours and then immediately stored at -80°C until further analysis. The study was approved by the NTEC-CUHK Joint Clinical Research Ethics Committee (CREC Ref No: 2021.136). Written informed consent was provided by all subjects.
[0177] result
[0178] The recurrence diagnostic model was validated using follow-up stool samples in a prospective cohort.
[0179] In the validation cohort, 50 consecutive subjects who had undergone polypectomy were recruited and provided eligible stool samples prior to bowel preparation for colonoscopy. qPCR testing was performed before colonoscopy and then compared with the colonoscopy findings. The same logistic regression model involving m3, Ch, and Fn follow-up levels, along with the same cutoff values from the discovery / training cohort, was applied to the validation cohort. Of these 50 subjects, 34 were identified as high-risk by the m3ChFn model (scores above the cutoff), of whom 23 were confirmed to have adenoma recurrence, yielding a positive predictive value (PPV) of 67.6% for our model. The remaining 16 subjects were identified as low-risk by the m3ChFn model, of whom 11 were confirmed to have no adenoma recurrence, yielding a negative predictive value (NPV) of 68.8% for our model. Importantly, our model detected high-risk individuals in 5 patients with recurrent advanced adenoma. Figure 5 (A1).
[0180] Compared with patients without recurrent adenomas, the m3ChFn model showed a significantly higher overall score in patients with recurrent adenomas (P = 0.03), with an AUROC of 0.679 in the validation cohort (95% CI: 0.527–0.831). Figure 5The m3ChFn model showed a sensitivity of 82.1% for recurrent adenomas (100% for recurrent advanced adenomas) and a specificity of 50%. On the other hand, FIT detected only 2 out of 28 recurrent adenomas (sensitivity = 7.1%) and 0 out of 5 recurrent advanced adenomas (sensitivity = 0%), although it had a relatively high specificity (95.5%). Figure 5 (A2). Our model (68.0%; 34 / 50) had significantly higher overall diagnostic accuracy than FIT (46.0%; 23 / 50) (Fisher precision test P<0.05).
[0181] All patents, patent applications and other publications cited in this application, including GenBank accession numbers and equivalents, are incorporated herein by reference in their entirety for all purposes.
[0182] Table 3. Nucleotide sequences of primers and probes used in this study
[0183] Primers Sequence (5'-->3') Bc-F TCCATCCGCAAGCCTTTACT(SEQ ID NO:1) Bc-R GCTTCCGGTGCCATTGACTA(SEQ ID NO:2) m3-F AATGGGAATGGAGCGGATTC(SEQ ID NO:3) m3-R CCTGCACCAGCTTATCGTCAA(SEQ ID NO:4) Ch-F GGGCTGCGGAAGCAACTTA(SEQ ID NO:5) Ch-R GATGACCTCGCCCTGATCAT(SEQ ID NO:6) FN-F TTCAATAAAAGTGGCAGGTCAAG(SEQ ID NO:7) FN-R TAACAACACATGCAGGTCAATGG(SEQ ID NO:8) Ri-F CGGATTTGCAGTGGCAAGTT(SEQ ID NO:9) Ri-R TGATTGCAGACGCCAATGTC(SEQ ID NO:10) CF CGTCAGCTCGTGYCGTGAG(SEQ ID NO:11) CR CGTCRTCCCCRCCTTCC(SEQ ID NO:12) probe Sequence (5'-->3') Bc TTCATCATCACAGCCGACAACGCA(SEQ ID NO:13) m3 AAGCCTGCGGAACCACAGTTACCAGC(SEQ ID NO:14) Ch ACCACCACACAGGACGGAAAGATTCTCC(SEQ ID NO:15) FN ACTCGAACCCCCAACCCTCGGTTT(SEQ ID NO:16) Ri CGTGAAAATCCGCGCATCTGGC(SEQ ID NO:17) C ttaagtCCCRYAACGAGCGCAACCC(SEQ ID NO:18)
[0184] Table 4. Clinical characteristics of the subjects recruited in this study
[0185]
[0186] *The size of the largest lesion in each patient was taken into account.
[0187] Baseline data are missing for 5 patients in Group II.
[0188] References
[0189] 1.Allemani C,Matsuda T,Di Carlo V,et al.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37513 025patients diagnosed with one of 18cancers from 322population-basedregistries in 71countries.Lancet 2018;391:1023-1075.
[0190] 2.Lieberman DA,Rex DK,Winawer SJ,et al.Guidelines for colonoscopysurveillance after screening and polypectomy:a consensus update by the USMulti-Society Task Force on Colorectal Cancer.Gastroenterology 2012;143:844-857.
[0191] 3.Imperiale TF,Ransohoff DF,Itzkowitz SH,et al.Multitarget stoolDNAtesting for colorectal-cancer screening.N Engl J Med 2014;370:1287-97.
[0192] 4.deVos T,Tetzner R,Model F,et al.Circulating methylated SEPT9 DNA inplasma is a biomarker for colorectal cancer.Clin Chem 2009;55:1337-46.
[0193] 5.Liang JQ,Li T,Nakatsu G,et al.A novel faecal Lachnoclostridiummarker for the non-invasive diagnosis of colorectal adenoma and cancer.Gut2020;69:1248-1257.
[0194] 6.Irrazabal T,Belcheva A,Girardin SE,et al.The multifaceted role ofthe intestinal microbiota in colon cancer.Mol Cell 2014;54:309-20.
[0195] 7.Yu J,Feng Q,Wong SH,et al.Metagenomic analysis of faecal microbiomeas a tool towards targeted non-invasive biomarkers for colorectal cancer.Gut2017;66:70-78.
[0196] 8.Nakatsu G,Li X,Zhou H,et al.Gut mucosal microbiome across stages ofcolorectal carcinogenesis.Nat Commun 2015;6:8727.
[0197] 9.Dai Z,Coker OO,Nakatsu G,et al.Multi-cohort analysis of colorectalcancer metagenome identified altered bacteria across populations anduniversal bacterial markers.Microbiome 2018;6:70.
[0198] 10.Tilg H,Adolph TE,Gerner RR,et al.The Intestinal Microbiota inColorectal Cancer.Cancer Cell 2018;33:954-964.
[0199] 11.Wong SH,Zhao L,Zhang X,et al.Gavage of Fecal Samples From PatientsWith Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-Free andConventional Mice.Gastroenterology 2017;153:1621-1633e6.
[0200] 12.Kostic AD,Chun E,Robertson L,et al.Fusobacterium nucleatumpotentiates intestinal tumorigenesis and modulates the tumor-immunemicroenvironment.Cell Host Microbe 2013;14:207-15.
[0201] 13.Rubinstein MR,Wang X,Liu W,et al.Fusobacterium nucleatum promotescolorectal carcinogenesis by modulating E-cadherin / beta-catenin signaling viaits FadA adhesin.Cell Host Microbe 2013;14:195-206.
[0202] 14.Yu T,Guo F,Yu Y,et al.Fusobacterium nucleatum PromotesChemoresistance to Colorectal Cancer by Modulating Autophagy.Cell 2017;170:548-563e16.
[0203] 15.Tsoi H,Chu ESH,Zhang X,et al.Peptostreptococcus anaerobius InducesIntracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferationand Causes Dysplasia in Mice.Gastroenterology 2017;152:1419-1433e5.
[0204] 16.Liang Q,Chiu J,Chen Y,et al.Fecal Bacteria Act as Novel Biomarkersfor Noninvasive Diagnosis of Colorectal Cancer.Clin Cancer Res 2017;23:2061-2070.
[0205] 17.Liang JQ,Wong SH,Szeto CH,et al.Fecal microbial DNA markers servefor screening colorectal neoplasm in asymptomatic subjects.J GastroenterolHepatol2020.
[0206] 18.Rutter MD,East J,Rees CJ,et al.British Society ofGastroenterology / Association of Coloproctology of Great Britain and Ireland / Public Health England post-polypectomy and post-colorectal cancer resectionsurveillance guidelines.Gut2020;69:201-223.
[0207] 19.Gupta S,Lieberman D,Anderson JC,et al.Recommendations for Follow-Up After Colonoscopy and Polypectomy:A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer.Gastrointest Endosc 2020;91:463-485e5.
[0208] 20.Youden WJ.Index for rating diagnostic tests.Cancer 1950;3:32-5.
[0209] 21.DeLong ER,DeLong DM,Clarke-Pearson DL.Comparing the areas undertwo or more correlated receiver operating characteristic curves:anonparametric approach.Biometrics 1988;44:837-45.
[0210] 22.Dulal S, Keku TO. Gut microbiome and colorectal adenomas. Cancer J 2014; 20:225-31.
[0211] 23.Shen XJ, Rawls JF, Randall T, et al. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes 2010; 1:138-47.
[0212] 24.Yu SY, Xie YH, Qiu YW, et al. Moderate alteration to gut microbiota brought by colorectal adenoma resection. J Gastroenterol Hepatol 2019; 34:1758-1765.
[0213] 25.Xia X, Wu WKK, Wong SH, et al. Bacteria pathogens drive host colonic epithelial cell promoter hypermethylation of tumor suppressor genes in colorectal cancer. Microbiome 2020; 8:108.
[0214] 26.Zhu X, Parks PD, Weiser E, et al. National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences. Cancer Prev Res (Phila) 2021. Informal Sequence Listing
[0215] Primers Sequence (5-->3) Bc-F TCCATCCGCAAGCCTTTACT(SEQ ID NO:1) Bc-R GCTTCCGGTGCCATTGACTA(SEQ ID NO:2) m3-F AATGGGAATGGAGCGGATTC(SEQ ID NO:3) m3-R CCTGCACCAGCTTATCGTCAA(SEQ ID NO:4) Ch-F GGGCTGCGGAAGCAACTTA(SEQ ID NO:5) Ch-R GATGACCTCGCCCTGATCAT(SEQ ID NO:6) FN-F TTCAATAAAAGTGGCAGGTCAAG(SEQ ID NO:7) FN-R TAACAACACATGCAGGTCAATGG(SEQ ID NO:8) Ri-F CGGATTTGCAGTGGCAAGTT(SEQ ID NO:9) Ri-R TGATTGCAGACGCCAATGTC(SEQ ID NO:10) C-F CGTCAGCTCGTGYCGTGAG(SEQ ID NO:11) C-R CGTCRTCCCCRCCTTCC(SEQ ID NO:12) Probe Sequence (5'-->3') Bc TTCATCATCACAGCCGACAACGCA(SEQ ID NO:13) m3 AAGCCTGCGGAACCACAGTTACCAGC(SEQ ID NO:14) Ch ACCACCACACAGGACGGAAAGATTCTCC(SEQ ID NO:15) FN ACTCGAACCCCCAACCCTCGGTTT(SEQ ID NO:16) Ri CGTGAAAAATCCGCGCATCTGGC(SEQ ID NO:17) C ttaagtCCCRYAACGAGCGCAACCC(SEQ ID NO:18)
[0216] SEQ ID NO:19
[0217] >A Lachnoclostridium sp. m3 (gene ID 482585)
[0218]
[0219] SEQ ID NO:20
[0220] >Clostridium hathewayi (now known as Hungatella hathewayi) (gene ID 2736705)
[0221] ATGCCTATACTTCAGCAGCTTCTCACATTAGTAGAGCAGCACTTCGGTAACAAATGCGAAATCGTGCTTCATGATCTGACAAAGGATTACAACCATACCATTGTCGATATCCGAAACGGAGACATTACCCATCGTTCCATCGGGGGCTGCGGAAGCAACTTAGGGCTGGAAGTCCTGCGCGGAACCGTGCTGGATGGGGATCGTTTTAACTATGTTACCACCACACAGGACGGAAAGATTCTCCGTTCCTCATCGATCTATCTAAAAAATGATCAGGGCGAGGTCATCGGATCGATCTGCGTGAACCTGGATATCACAGAGACACTTCAGTTTGAAGGGTATTTACGCCAGTTTAACCAGTTTGACAGCTTTACTTCCAACGACGAGGAGATTTTCGCTCCCGACGTGAATAATCTTCTCAGCCATCTGATTCAGATGGGACAGGAACAGATCGGAAAGCCTGCGCTGGAGATGAACAAGAACGAGAAGATTGAGTTTATCCGTTTCCTTGACCAGAAAGGAGCATTCCTCATCACGAAGTCCGGGGAACAGATCTGTGAACTTCTGGGAATCAGCAAATTTACCTTTTATAATTACCTTGAAAGCAGCCGCAGCCAGTCGGATTCG
[0222] SEQ ID NO:21
[0223] >Fusobacterium nucleatum (Fn) (gene ID 1704941)
[0224] TCTGCAAAAGAAAAAGTTGCTGCATTAGTTGCTGCATTAAAAGCAGATGGATATTTTACTGTTGGTATCCCTCTGATACACCAAGGAAAATCTGAAAGGTGTAAGTGCTGGTAAAGGGATTGGAGATAAAAAGAATGAAGCTAATTGAAACTTAGCAAAA CAAGCTGGAGCTTCTATTGGTTCTTCTCGTCCAGTGGCAGAAACATTGCAATATGTACCTCTTGACCGTTATGTAGGAATGTCAGGACAAAAATTTGTTGGAAACCTTTATAGCTTGTGGAATTTCAGGAGCTTTACAACTTTAAAAGGAATTAAAGATGCAACAACAA TAGTTGCTATAAATACAAACTCAAAATGCTCCAATATTTAAGAATGCAGACTATGGAATAGTTGGAGATTTAGCAGAAATTTTACCTTTTAACTAAGGAATTAGATAATGGAGAAGCTAAAAAAGATGCACCACCTATGAAGAAAATGAAGAGGTTTACCTAGAGTAGT GTATAGTCCTCATGTATATGTATGTAGTGGTTGTGGACATGAATACCTGATTTAGGAGATGAAGATTCTGACATAAAACCAGGAACTAGATTAAGATTTACCAAGATTGGACTTGTCCTGATTGTGGAGATCCAAAATCTGGATATAGATGCAAAAAAATAA
[0225] SEQ ID NO:22
[0226] >Bacteroides clarus(Bc)(gene ID 370640)
[0227] sequence list <110> The Chinese University of Hong Kong <120> Assessing the risk of recurrence of colorectal adenomas using non-invasive methods <150> US 63 / 116,104 <151> 2020-11-19 <150> US 63 / 196,582 <151> 2021-06-03 <160> twenty two <170> SIPOSequenceListing 1.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <400> 1 tccatccgca agcctttact 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <400> 2 gcttccggtg ccattgacta 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <400> 3 aatgggaatg gagcggattc 20 <210> 4 <211> twenty one <212> DNA <213> Artificial Sequence <400> 4 cctgcaccag cttatcgtca a twenty one <210> 5 <211> 19 <212> DNA <213> Artificial Sequence <400> 5 gggctgcgga agcaactta 19 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <400> 6 gatgacctcg ccctgatcat 20 <210> 7 <211> twenty three <212> DNA <213> Artificial Sequence <400> 7 ttcaataaaa gtggcaggtc aag twenty three <210> 8 <211> twenty three <212> DNA <213> Artificial Sequence <400> 8 taacaacaca tgcaggtcaa tgg twenty three <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <400> 9 cggatttgca gtggcaagtt 20 <210> 10 <211> 20 <212> DNA <213> Artificial Sequence <400> 10 tgattgcaga cgccaatgtc 20 <210> 11 <211> 19 <212> DNA <213> Artificial Sequence <400> 11 cgtcagctcg tgycgtgag 19 <210> 12 <211> 17 <212> DNA <213> Artificial Sequence <400> 12 cgtcrtcccc rccttcc 17 <210> 13 <211> twenty four <212> DNA <213> Artificial Sequence <400> 13 ttcatcatca cagccgacaa cgca twenty four <210> 14 <211> 26 <212> DNA <213> Artificial Sequence <400> 14 aagcctgcgg aaccacagtt accagc 26 <210> 15 <211> 28 <212> DNA <213> Artificial Sequence <400> 15 accaccacac aggacggaaa gattctcc 28 <210> 16 <211> twenty four <212> DNA <213> Artificial Sequence <400>16 actcgaaccc ccaaccctcg gttt 24 <210>17 <211>23 <212>DNA <213>Artificial Sequence <400>17 cgtgaaaaat ccgcgcatct ggc 23 <210>18 <211>25 <212>DNA <213>Artificial Sequence <400>18 ttaagtcccr yaacgagcgc aaccc 25 <210>19 <211>1935 <212>DNA <213>A Lachnoclostridium sp. m3 <400>19 aatatccgat atggcaacgg agctctggta gtagtccggg caagggaaaa ccttgtacat 60 ggcgaagcag agcagattac cttcaatact aaaatattag aaaggtgcgt gaggcatttg 120 agaaatccga ttgaagtatt gaaaactcta caagagaaag caggcaacga gaactatcaa 180 tttgaacgcc tgtaccgaaa tctgtacaac gaggagtttt tcctattggc atacggaaat 240 ctctctgcaa aagagggaaa tctgaccaag ggaacagacg gcgccacaat agacggaatg 300 ggaatggagc ggattcgcaa gctgattgaa agcctgcgga accacagtta ccagccgtcc 360 cctgcgagac gtgcctatat cccaaaatct aatggaaaac ggcgtccgtt aggcataccc 420 tctgttgacg ataagctggt gcaggaagtt gtgaggttaa ttctcgaaag tgtgtatgaa 480 agcaatttt ctgaacattc gcatggttt agaccgaaca ggagctgtca cacggcactg 540 acccagattc aaagaaactt cacaggggtt aaatggttca ttgaggggga catcaaaggt 600 tattttgaca ccatcgacca ccatatcctt gtggatattt taagaaggcg cataaaggac 660 gaatacctaa tctcgctgaat atggaaattt ctgaaagccg gatacttaga agatgggaaa 720 ttcaatccta cctattccgg cactccgcaa ggctcggtca tcagtccaat acttgccaat 780 atctacctta acgaattcga tacctatgtt gaagaataca tagagaaatt caaccgtggt 840 aaaagacgtg aaaaaacag tgagtatcgc ttttatagtg atggcgcatc gaaactgagg 900 gtaaagtacc gcggggttatg ggaataatg acagccgatg aaaaagaaaa agccaaatgt 960 gaagtaatg agctcatgaa aaaagcaaaa cagattccag ctatgaatcc gatggacagc 1020 attaccgcc gtctgctcta ttgcaggtat gcggatgatt ttatttgcgg agtaatcgga 1080 agcaaggaag atgcagaaac catcaaggct gattttagcc ggtacctgaa agaaaagctg 1140 ggactggata tgtcggaaga aaagacactg attacacact caaacgaaaa agcggcgttc 1200 cttggctacg aaatcgctgt ttccagaagc aatgaataca aaaagataag caacggacag 1260 aaggcaagaa cctttaatgg gcgtgttcat ctatttatgc cacataataa atgggttaag 1320 aagctgacca gttgcggagc aatggaaatc aaacagcagg acggcaaaga aatatggaaa 1380 ccgcaggcga ggaaagacct catcaacaaa gagccgattg aaatcctaag catttacaat 1440 gccgaaattc gtgggctgta caattattat tgtttggcaa gcaacgtatg caagctgcag 1500 aaatattact acatcatgga atacagcatg taccagacgt ttgcagcgaa gtaccgtgat 1560 aatttgcgga aaacgattaa caagcatacc cgaaacggcg tgtttggtgt cagctacact 1620 acaaaaaccg gcaacgagaa acgggcgaca ttcgtgaaag gaagcttcca aaaacggact 1680 gtcagcttag attacagtga tgaaatcccc tcttatcctg ccgcaaaata tagcggaaa 1740 aacggcttaa ttgagcggtt acagggtgga aaatgtgaac tatgcggaca gcagaccgac 1800 aatgtaaaag ttcatcatgt caggaagctg aaagaattag ccggtatgaa agaatgggaa 1860 agaaaaatgg ttcagatgaa cagaaaaact ctggttgttt gtaatacatg ttatggaaac 1920 ataacaggca agtaa 1935 <210>20 <211>627 <212>DNA <213>Clost ridium hathewayi <400>20 atgcctatac ttcagcagct tctcacatta gtagagcagc acttcggtaa caaatgcgaa 60 atcgtgcttc atgatctgac aaaggattac aaccatacca ttgtcgatat ccgaaacgga 120 gacattaccc atcgttccat cgggggctgc ggaagcaact tagggctgga agtcctgcgc 180 ggaaccgtgc tggatgggga tcgttttaac tatgttacca ccacacagga cggaaagatt 240 ctccgttcct catcgatcta tctaaaaaat gatcagggcg aggtcatcgg atcgatctgc 300 gtgaacctgg atatcacaga gacacttcag tttgaagggt atttacgcca gtttaaccag 360 tttgacagct ttacttccaa cgacgaggag attttcgctc ccgacgtgaa taatcttctc 420 agccatctga ttcagatggg acaggaacag atcggaagc ctgcgctgga gatgaacaag 480 aacgagaaga tgagtttat ccgttttcctt gaccagaaag gagcattcct catcacgaag 540 tccggggaac agatctgtga acttctggga atcagcaat tacctttta taattacctt 600 gaaagcagcc gcagccagtc ggattcg 627 <210> 21 <211> 687 <212> DNA <213> Fusobacte rium nucleatum <400> 21 tctgcaaag aaaaagttgc tgcattagtt gctgcattaa aagcagatgg atatgatttt 60 actgttgta tcccttga tacaccata ggaaatctg aaagagttgt aagtgctggt 120 aaagggattg gagaaaaa gattgag ctattgaa acttagcaa acagctgga 180 gcttctattg gttctctcg tccagtggca gaacattgc atatgtacc tcttgaccgt 240 tatgtaggaa tgtcaggaca aaatttgtt ggaaaccttt atagcttg tggaatttca 300 ggagctttac aacattaaa aggaatttaa gatgcaacaa catagttgc tataaataca 360 aactcaaatg ctccaatatt taagaatgca gactatggaa tagttggaga tttagcagaa 420 attttacctt tattaacta ggaattagat atggagag ctaaaaaga tgcaccacct 480 atgaagaaaa tgaagagt tatacctaga gtagtgtata gtcctcatgt atatgtatgt 540 agtggttgtg gatagata caatcctgat ttaggagatg aagattctga cataaaacca 600 ggaactagat ttaagattt accagagat tggacttgtc ctgattgtgg agatccaaaa 660 tctggatata tagatgcaa aaataa 687 <210> 22 <211> 1161 <212> DNA <213> Bacte wheels Russian cla <400> 22 atgaaaatca aacaattagc gaaaagcgca tcattcttgc tggtggcagg ttcattagt 60 ttactattc cgtcgtgtag cagtgaagaa gaatcatca tccttcagga tgtaaagta 120 aacagtgaaa gcttcaatct ggccgaagac ggcagtacga ccatagaagt caagtagta 180 cccgaaaata ctccaatagc caaagccgta ctcagcacat cattatta tgaagcggt 240 gttttcgaag taacccgact cactcccaaa ggtaacggtg tatggcagat agcagcaaaa 300 gtaaaggact tctcacgcat tcaaacggt caggacgtaa tactttccgt ctatcaggaa 360 gataatgt atatccaac cacattgaaa ataacgacc catatagcat cgaggtaaa 420 tatacaccgg tccatccgca agcctttact ttctacagtg ccgaagacgg caactgatg 480 gagattccgt tcatcac agccgacac gcagccgacc tgccgccat cagctacgac 540 atataagg tagtcaatgg caccggaagc tctacaccca gcataagtat cacacatttc 600 gcaatagctc cgatgacagg taaaacaggc ttctatctgc aagtggataa cgcccaactc 660 gaaacggtaa aaaaagccat cacaccatc gctttttgg actgccggggt tatgataacc 720 ggccctaacg gccgtgttgc ctatactcct gtgcgcctca ttgttttctc tccgaagtgc 780 atcatcagg acgaccaac cagcctgctg catacagaat tgtccgcccc ggagtttaat 840 agacaaatca ccatagatat gacccacgat ttttatcgtt tgggcaaaca gatgataaa 900 acaaccttg aggcgtttga aaaccgaggc ttgtataact cacaggaga atggcagat 960 gcagaccctc agttcattc gttggttt accactcagg gcaaaaatac aacatgtaac 1020 gtaactttaa aacatgatgc cacaatcct gcaatcggca cttaccacat ggtagaacgc 1080 ctaaaaggat attgggaata tgacggaaag aatatccga ccgtttgtac agacctgcaa 1140 ttccaaatca cgattaaata in 1161
Claims
1. A system for assessing the risk of recurrence of colorectal adenoma in an individual after resection of colorectal cancer or adenoma, the system comprising means for performing the following: (a) Before resection of colorectal cancer or adenoma, obtain baseline levels of the following bacterial species from the first stool sample collected from the individual: those carrying genetic markers. m3 of Lachnoclostridium Species ( m3 ), Fusobacterium nucleatum ( Fn ) and Clostridium perfringens ( Ch ); (b) Obtain the follow-up level of the bacterial species from a second stool sample collected from the individual after resection of colorectal cancer or adenoma; (c) Based on the bacterial species Fn , m3 and Ch The baseline level and the follow-up level are used to calculate a comprehensive score; and (d) If the composite score is detected to be higher than the standard control value, it is determined that the individual has an increased risk of recurrence of colorectal adenoma.
2. The system according to claim 1, wherein, The combined score of the baseline and follow-up level for the bacterial species is calculated as follows: I 10 + (β i Fn 随访 – β j Fn 基线 ) + (β k m3 随访 – β l m3 基线 ) + (β m Ch 随访 – β n Ch 基线 )。 3. The system according to claim 1, wherein, m3 The genome includes the nucleotide sequence of SEQ ID NO:19, or therein Ch The genome includes the nucleotide sequence of SEQ ID NO:20, or therein Fn The genome includes the nucleotide sequence of SEQ ID NO:
21.
4. The system according to claim 1, wherein, The individual underwent polypectomy to remove a colorectal adenoma.
5. The system according to claim 1, wherein, Steps (a) and (b) each include obtaining the bacterial species. Fn , m3 and Ch The specific levels of DNA or RNA described therein.
6. The system according to claim 1, wherein, Steps (a) and (b) each include a polymerase chain reaction (PCR) for determining the level of the bacterial species.
7. The system according to claim 6, wherein, The PCR is either quantitative polymerase chain reaction (qPCR) or reverse transcription-polymerase chain reaction (RT-PCR).
8. The system according to claim 1, wherein, The second stool sample was collected from the individual one to five years after the removal of colorectal cancer or adenoma.
9. The system according to claim 8, wherein, The second stool sample was collected from the individual approximately one year after the removal of the colorectal cancer or adenoma.
10. A system for assessing the risk of recurrence of colorectal adenoma in an individual after resection of colorectal cancer or adenoma, the system comprising means for performing the following: (a) The following were obtained from a stool sample collected from the individual after the removal of colorectal cancer or adenoma: Three bacterial species Fn , m3 and Ch The overall score of the level is calculated as follows: I3 + β7 Fn + b8 m3 + b9 Ch ; (b) If the composite score is found to be higher than the standard control value, it is determined that the individual has an increased risk of recurrence of colorectal adenoma.
11. The system according to claim 10, wherein, m3 The genome includes the nucleotide sequence of SEQ ID NO:19, or therein Ch The genome includes the nucleotide sequence of SEQ ID NO:20, or therein Fn The genome includes the nucleotide sequence of SEQ ID NO:
21.
12. The system according to claim 10, wherein, The individual underwent polypectomy to remove a colorectal adenoma.
13. The system according to claim 10, wherein, Step (a) includes obtaining the bacterial species. Fn , m3 and Ch The specific levels of DNA, RNA, or proteins described therein.
14. The system according to claim 10, wherein, Step (a) includes polymerase chain reaction (PCR), which is used to determine the level of the bacterial species.
15. The system according to claim 14, wherein, The PCR is either quantitative polymerase chain reaction (qPCR) or reverse transcription-polymerase chain reaction (RT-PCR).
16. The system according to claim 10, wherein, The stool samples were collected from the individuals one to five years after the removal of colorectal cancer or adenoma.
17. The system according to claim 10, wherein, The stool samples were collected from the individual approximately one year after the removal of colorectal cancer or adenoma.
18. Used for determining bacterial species Fn, m3 and Ch The use of multiple reagents at various levels in the preparation of a kit for assessing an individual's risk of recurrence of colorectal adenoma after resection of colorectal cancer or adenoma, said kit comprising: (1) A first container containing materials for determining bacterial species. Fn (2) A second container containing reagents for determining bacterial species. m3 The reagent level; and (3) a third container containing reagents for determining bacterial species. Ch The reagent at the level of [unclear].
19. The use according to claim 18, wherein the reagent in each of the containers is a reagent for polymerase chain reaction (PCR).
20. The use according to claim 19, wherein the PCR is qPCR or RT-PCR.
Citation Information
Patent Citations
Method of encapsulating biologically active materials in lipid vesicles
US4235871A
Masking of liposomes from RES recognition
US4501728A
Liposomes with enhanced circulation time
US4837028A
General method for producing and selecting peptides with specific properties
US5010175A
Methods of detecting picornaviruses in biological fluids and tissues
US5075212A
